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 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Sjukdomen malaria orsakars av parasiten Plasmodium falciparum som sprids av 
malariamyggan Anopheles. Parasiten infekterar och förökar sig i de röda blodkropparna 
tills blodkropparna sprängs och parasiterna kan invadera nya. Om malariaparasiten inte 
behandlas är det stor risk att patienten dör. Varje år dör cirka 1 miljon människor av 
malaria. Majoriten är barn yngre än 5 år och gravida kvinnor i Afrika söder om Sahara.  
 
Malaria går att behandla, och det finns ett antal fungerande läkemedel. Tyvärr är det 
oftast bara en tidsfråga innan malariaparasiten utvecklar resistens mot 
malarialäkemedel och detta kan få katastrofala konsekvenser när få eller inga andra 
fungerande läkemedel finns att tillgå. Det läkemedel som används för behandling av 
malaria i de flesta afrikanska länder idag heter artemether-lumefantrine (Coartem
® 
eller 
Riamet
®
) och är en så kallad artemisininbaserad kombinationsbehandling (ACT). Det 
är en kombination av ett mycket aktivt artemisininderivat som snabbt reducerar 
mängden parasiter och ett annat läkemedel som inte är lika effektivt men är kvar länge i 
kroppen och dödar av de sista kvarvarande parasiterna. Denna avhandling handlar om 
att förstå hur parasiten utvecklar resistens mot kombinationsbehandlingen artemether-
lumefantrine.  
 
För att kunna förstå hur resistens utvecklas är det en stor fördel att veta hur läkemedlet 
verkar. För det allra flest malarialäkemedel är detta dock fortfarande en gåta, detta 
gäller även artemether-lumefantrine. Det har visats att resistens mot malarialäkemedlet 
klorokin beror på en förändrad aminosyra i ett transportprotein som transporterar 
läkemedlet ut ur parasitens inre vakuol där det annars kan påverka parasitens 
interaktion med hemoglobin. Den gen som denna avhandling handlar mest om heter 
Plasmodium falciparum multi-läkemedelstransportör (pfmdr1) och är en gen som kodar 
för ett protein som är en pump som kan pumpa in diverse olika läkemedel i parasitens 
inre vakuol. Mutationer i denna gen kan påverka transporten av läkemedel in och ut ur 
den inre vakuolen. Förändringar i transportkapaciteten skulle kunna leda till 
resistensutveckling. Till exempel om läkemedlet transporteras till ett ställe där det inte 
kan verka kan parasiten undkomma dess effekt.   
 
Genom att kombinera kliniska fältstudier i Tanzania med molekylärbiologiska studier 
på laboratoriet har vi försökt förstå vad som påverkar resistensutvecklingen. För att 
förstå hur resistens utvecklas mot lumefantrine har vi jämfört parasitens DNA från 
insjuknade malariapatienter före behandling med de patienter som får tillbaka parasiter 
upp till åtta veckor efter behandling.  
 
För att avgöra om det utvecklats resistens mot ett läkemedel behöver man kunna skilja 
på två olika sorters återkommande parasiter. De ena är de som faktiskt är resistenta och 
som varit kvar sedan påbörjad behandling, men i så små mängder att de inte har blivit 
upptäckta med mikroskopi. De andra är nya parasiter som patienten fått från ett nytt 
myggbett under pågående behandling. Det finns en molekylär metod att skilja på dessa 
olika sorters återkommande parasiter genom att jämföra parasiternas DNA före 
behandling och när parasiterna kommer tillbaka. Denna metod har dock visat sig ha ett 
 flertal brister vilket resulterar i att läkemedlen ofta bedöms vara bättre än vad de 
faktiskt är samt försvårar arbetet med förstå hur resistens utvecklas. 
 
För att komma tillrätta med dessa problem har vi utvecklat en ny metod. Vi mätte 
läkemedelskoncentrationer av lumefantrine (det läkemedel som är kvar länge efter 
avslutad behandling), strax efter avslutad behandling och med hjälp av tidigare 
information om hur snabbt läkemedel försvinner ur kroppen på kunde vi uppskatta hur 
mycket läkemedel som fanns kvar när parasiterna kom tillbaka. Sedan jämförde vi de 
olika patienternas koncentrationer vid återkommande infektion med genetiska 
förändringar i pfmdr1-genen. Vi såg då att parasiter med aminosyrakombinationen 
NFD, hädanefter benämnda ”okänsliga”, kunde infektera patienter med 15 gånger 
högre lumefantrinekoncentrationer än parasiter med de så kallade ”känsliga” YYY 
uppsättningen.  
 
Vi kunde också se att tiden efter en avslutad behandling som en patient är skyddad mot 
nya malariainfektioner kan variera med upp till tre veckor beroende på om de nya 
malariainfektionerna är så kallat ”okänsliga” eller ”känsliga”.  
 
Genom att jämföra parasit-DNA hos patienter som kommit till en vårdcentral i 
Tanzania från 2004 till 2011 har vi kunnat se att förändringarna i pfmdr1-genen som 
resulterar i ”okänsliga” parasiter har ökat signifikant sedan artemether-lumefantrine 
började användas 2006. 
 
Sammanfattningsvis har den här avhandlingen visat att trots att mycket tyder på att 
artemether-lumefantrine är ett effektivt läkemedel så kan det finnas anledning att vara 
orolig för hur länge detta kommer att fortgå. Det verkar som om genetiska förändringar 
i genen pfmdr1 kan vara ett första steg mot resistensutveckling mot lumefantrine.  
 ABSTRACT 
Malaria is a devastating disease which kills ~1 million people yearly. The vast majority 
of lives lost due to malaria are children and pregnant women in sub-Saharan Africa. 
Although malaria is a treatable disease it continues to be one of the major causes of 
death, especially in poor settings. Chemotherapy is the key to control the disease, 
decrease the burden of malaria and save lives. The malaria parasites ability to develop 
resistance towards antimalarial drugs is therefore a major concern. Artemether-
lumefantrine (Coartem
®
, Novartis) is currently the most used treatment for 
uncomplicated Plasmodium falciparum malaria. The aim of this thesis was to 
contribute to the understanding of the role of molecular markers in emerging 
artemether-lumefantrine resistant P. falciparum. 
 
This thesis is based on artemether-lumefantrine clinical trials designed to evaluate the 
efficacy and effectiveness of artemether-lumefantrine for treatment of uncomplicated P. 
falciparum malaria in children in Tanzania. We measured lumefantrine concentrations 
and investigated their correlation with cure rates and with tolerance/resistance 
associated markers within the parasite. Our focus was primarily on polymorphisms 
within P. falciparum multidrug resistance gene 1 (pfmdr1) and P. falciparum 
chloroquine transporter gene (pfcrt).  
 
One major finding is that lumefantrine blood drug concentrations in combination with 
pharmacokinetic parameters can be used to assess the relative importance of different 
single nucleotide polymorphisms for lumefantrine drug susceptibility in vivo. 
Lumefantrine blood drug concentrations after artemether-lumefantrine treatment were 
correlated with selection of recurrent infections with specific pfmdr1 N86, 184F and 
D1246 single nucleotide polymorphisms. 
 
Although artemether-lumefantrine was found to have excellent efficacy and 
effectiveness according to PCR adjusted cure rates, the number of recurrent infections 
were high and we observed an up to three week difference in post-treatment 
prophylactic effect depending on the pfmdr1 polymorphisms among recurrent 
infections. Since the introduction of artemether-lumefantrine as first line treatment for 
uncomplicated malaria in Tanzania in 2006, the prevalence of pfmdr1 N86, 184F and 
D1246 have increased significantly up to 2011.  
 
Overall, the results indicate that pfmdr1 is involved in the mechanism of resistance to 
lumefantrine. The increased prevalence of parasites carrying the pfmdr1 NFD 
haplotype could be an early warning of reduced artemether-lumefantrine efficacy.  
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 PREFACE 
 
My interest in malaria began when I had just turned 18. I had been looking forward to 
the day when I could start to donate blood and now I was finally 18 and Blodbussen 
was standing at Fyristorg in Uppsala. Before being allowed to donate blood I needed to 
fill out a form and one of the questions was if I had had malaria. I told the nurse that I 
had malaria when I was five years old and lived in Zambia. To my surprise she then 
told me that I was not accepted as a blood donor. I was disappointed but this also 
awakened my curiosity. Does this mean that I still have malaria parasites in my body? 
And if I do not, why have they decided upon a rule like this? To answer my questions I 
did my project work in upper secondary school (specialarbete) on this topic but I was 
not completely satisfied with my findings. When I again as a master student got the 
chance to choose my own project, I had just read about the success story of malaria 
control in Zanzibar, and was very happy that José Pedro Gil and Anders Björkman 
welcomed me back to the malaria world.  
 
My interest for antimalarial drugs started already during my childhood. I had the 
fortune to live with my family in rural Zambia between the ages of four and six, when 
my father worked for SIDA as an agricultural advisor. To avoid getting malaria we 
took antimalarial prophylaxis, crushed in jam, every day. My grandparents Pelle and 
Gertrud Malmberg came to visit us and took antimalarial prophylaxis just as we did. 
However, my grandmother Gertrud was unlucky and got a very unusual side effect. She 
could no longer produce her own platelets and was therefore dependent on donated 
blood. She was sick for two years and then she died. My five year old I believed that 
my dear grandmother only came because it was my biggest wish. In my self-centred 
world I also then drew the conclusion that it was my fault that she had to take the 
prophylaxis which had made her sick and eventually killed her. It was quite a burden 
for me to carry. Today I know better, this book is for you Gertrud.  
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1 INTRODUCTION 
1.1 GLOBAL BURDEN OF MALARIA 
Malaria is a devastating disease killing approximately one million people every year 
(1). The vast majority (~90%) of these lives are lost in Sub-Saharan Africa, mainly 
among children under five years of age and pregnant women. In 2010, while World 
Health Organization (WHO) estimated there to be 655 000 cases, a systematic analysis 
of global malaria mortality estimated the figure for 2010 to be 1 238 000 (95% 
uncertainty intervals 929 000-1 685 000) (1). It is to note that this report by Murray et 
al. has been challenged by the malaria community, especially regarding the use of 
clinical malaria (i.e. not microscopy confirmed cases), which is known to overestimate 
malaria cases (2, 3). Nevertheless, it is estimated that 3.3 billion people are at risk of 
getting malaria and an estimated 216 million episodes of malaria to occurred in 2010 
(4).  
 
Malaria is an entirely preventable and treatable disease. This reinforces the strong link 
between malaria and poverty (5). Poverty can influence the risk of getting sick in and 
dying from malaria, for example by not being able to afford adequate treatment and 
insecticide treated bed nets. Malaria can also play a role in maintaining poverty by for 
example reducing the number of working days, increase health expenses etc.  
 
The global burden of malaria increased between 1980 and 2010, with a peak at 2004. 
This increase was partly explained by increasing malaria death rates in the late 1980s 
and early 1990s, influenced by drug resistance, and an increased population at risk of 
malaria. Great achievements in reducing the number of deaths due to malaria have been 
seen, with a 32% reduction from 2004 to 2010 (1).  
 
 
1.2 SPECIES OF MALARIA 
Malaria is caused by a unicellular apicomplexan parasite of the genus Plasmodium. 
There are five species of Plasmodium that can infect humans, P. falciparum, P. vivax, 
P. malariae, P. ovale and P. knowlesi. P. falciparum will be the focus of this thesis as it 
is the by far the most common one in Africa, and the most lethal. P. vivax is the most 
geographically spread of the species infecting humans. It has the ability to enter a 
metabolically inactive state called hypnozoite and can relapse months or even years 
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after infection. Such a capacity has proven advantageous in settings with seasonal 
transmission. P. knowlesi is primarily a macaque parasite but was recently shown to be 
able to infect humans.  
 
 
1.2.1 Origin of Plasmodium falciparum 
The genus Plasmodium evolved about 130 million years ago during the period when 
flowering plants rapidly spread across the globe. P. knowlesi and P. falciparum belong 
to the linage Laverania subgenus and diverged most recently as compared to the other 
species able to infect humans (6). Recent evidence indicates that P. falciparum is 
actually not unique to humans as it has also been detected in gorillas and monkeys (7, 
8). This raises concerns regarding the feasibility to eliminate malaria from areas where 
these reservoirs are maintained. 
 
 
1.3 THE PLASMODIUM FALCIPARUM PARASITE 
The P. falciparum parasite contains approximately 5 500 genes, on 14 chromosomes. 
The vast majority (>95%) of the genome was sequenced in 2002. By then, it was 
determined as the most A-T rich genome ever sequenced (81%) (9).  
 
 
1.3.1 The Plasmodium falciparum life cycle 
The P. falciparum parasite has a complex lifecycle (Fig. 1). The infection is initiated 
when a parasite infected Anopheles mosquito, while taking a blood meal, injects saliva 
containing P. falciparum sporozoites, into the human host. The sporozoites are injected 
to the skin where at least according to mice models quite a few will stay (10). The 
remaining enters either the lymph or the blood stream. Mice models have shown that 
those who enter the lymph will reach the closes lymph node and invade there, and then 
get cleared by the immune system (11). Those who enter the peripheral blood system 
will have the liver as their final destination. They rapidly reach the liver, invade the 
hepatocytes and start the process of maturation towards schizonts. After 5-16 days the 
hepatocytes burst and release up to 40 000 merozoites (per schizont) into the blood 
stream. These invade red blood cells (RBC) and start the erytherocytic part of the life 
cycle. This is initiated with the ring stage, followed by the trophozoite stage, and 
thereafter schizont stage. After the schizont stage the RBC are lysed and 8-24 new 
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merozoites are released from each schizont, ready to invade new RBC and reinitiate the 
erytherocytic cycle. This synchronized rupture of RBC causes periodical fever attacks, 
which is a main clinical characteristic of malaria.  
 
 
Figure 1. The P. falciparum life cycle. Printed with kind permission from Dr. Christin Sisowath 
(Karolinska Institutet). Illustration by Leopold Roos. 
 
In a fraction of the intra-host parasite population, sexual forms, referred to as 
gametocytes, develop. These forms are essential for the second part of the malaria life 
cycle to take place. When an Anopheles mosquito takes a blood meal containing 
gametocytes, the parasite sexual phase is initiated within the gut of the mosquito. The 
male and female gametocytes fuse into a zygote and after sexual recombination an 
ookinete is formed. The ookinate traverse the lining of the midgut and until it gets 
between the two membranes facing the hemocoel. An oocyst is formed and sporozoites 
start to bud off (sporogony). When the oocyst ruptures, thousands of sporozoites are 
released into the hemocoel and migrate to the salivary glands of the vector. The P. 
falciparum life cycle is completed when these sporozoites are injected into a human. 
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1.3.1.1 The digestive vacuole  
The cell biology of the parasite is complex, including regular organelle structures such 
as the endoplasmatic reticulum, the golgi system, the mitochondrion (even though not 
as involved in energy metabolism as in other organisms (12, 13), but also specific 
structures, like the apicoplast. In the context and the theme of this thesis the major 
compartment of interest is the digestive vacuole. This will be described in further detail. 
During the intra-erytherocytic cycle the parasite develops within the RBC, where it 
degrades ~80% of the haemoglobin within the RBC. Haemoglobin is the parasites main 
source of amino acids. The degradation of this complex molecule takes place within an 
acidic compartment called the digestive vacuole. The heamoglobin is ingested and 
transported to the digestive vacuole already during the early stages after invasion (12-
16h) (14). The ingestion is mediated by endocytic structures (cytostomes) at the surface 
of the parasite (15). Within the acidic digestive vacuole haemoglobin is degraded by 
specific peptidases (i.e. plasmepsins, falcipains, falciysin, dipeptidylpeptidases and 
aminopeptidases) into di-peptides which are transported to the cytoplasm and utilized 
by the parasite as amino acid source for proteins (16). When haemoglobin is degraded, 
the toxic rest-product haem is released. Haem is neutralized through crystallization 
towards a polymeric complex, the haemozoin, which is also referred to as the “malaria 
pigment”.  
 
 
1.3.2 The mosquito 
The origin of the name malaria comes from Latin’s mal aira which means bad air. The 
name referred to the badly smelling swampy areas which were associated with the 
disease. In 1735, Carolus Linnaeus presented in his thesis entitled “Hypothesis nova de 
febrium intermittentium causa” his theory that the intermittent fever was caused by clay 
particles in the water (17). This was later proven to be wrong when it became known 
that the agent causing the malaria disease was transmitted by mosquitos. 
 
All the Plasmodium species causing malaria in humans are transmitted by mosquitos of 
the genus Anopheles. The Anopheles is characterized by having its abdomen pointing 
upwards, as compared to parallel to the surface, when it is a resting position. There are 
many different species of Anopheles with different geographic locations. For example 
in south and coastal regions of Sweden the A. messeae is present. Different species 
differ in their capacity to transmit Plasmodium and A. gambiae and A. funestus which 
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dominate in sub-Saharan Africa are particularly efficient transmitters (18). One factor 
that influences transmission is the feeding behaviour of the mosquito, i.e. if they 
preferably feed on humans (anthropophily) or other animals (zoophily).  The A. 
gambiae and A. funestus are strongly anthropophilic.  
 
The Anopheles life cycle has four stages; egg, larva, pupa and imago. The first three 
stages are aquatic and last between 5-14 days, depending on temperature. Within a few 
days of becoming adult the anopheles mate, takes a blood meal, rest for 2-3 days and 
lay the eggs. This process is then repeated for the whole life span of in total 2-4 weeks. 
The female mosquito bites humans to get proteins from the blood, which are required 
for egg production. The time taken for P. falciparum to complete its life cycle within 
the mosquito depends on temperature. The parasites life cycle within the mosquito is 
expected to take 10-21 days. It has been shown in a mice model that development of P. 
yoelii increased with temperature, however maximum transmission prevalence was 
reached at 22°C (19).  
 
The use of insecticide treated bed nets is a highly effective tool to prevent transmission 
of Plasmodium as it blocks the mosquito’s ability to feed human blood. Indoor residual 
spraying of insecticides on indoor walls is used to kill mosquitos that prefer to rest 
indoors. The mosquito has a relative fast life cycle and thereby evolution. This favours 
resistance development, and its ability to develop resistance is a big threat to malaria 
control. The control measures insecticide treated net and indoor residual spraying  were 
developed based on the assumption that the mosquitos feed and rest indoors (20). 
However, if/when the mosquitos change behaviour, the use of these control measures 
might lose its importance. A recent report of previously unidentified P. falciparum 
vectors with the ability to feed outdoors and early in the evening is of great concern. 
These vectors were found in the highlands of western Kenya but there is no reason to 
believe that they could not be present also in other parts of Africa (21).  
 
 
1.3.3 The host 
Malaria has been with human since the origin of our species and it is the strongest 
known force for evolutionary selection in the recent history of the human genome. 
Malaria has been the main driving force behind for example sickle-cell disease, 
thalassemia and glucose-6-phosphatase dehydrogenase (G6PD) deficiency (22). 
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Erythrocyte (i.e. RBCs) defects can influence the malaria parasites ability to invade and 
cause disease. It was recently shown in both Zanzibar and Burkina Faso that slow 
metabolizers were more likely to be infected with resistant parasites suggesting that 
human genetics is also associated with parasite drug resistance (23, 24) 
 
 
1.4 DISEASE CHARACTERISTICS 
Malaria symptoms are fever, general malaise, headache, body ache, vomiting, 
diarrhoea, coughing and stomach ache. Other symptoms such as hypoglycemia, 
hyperlactatemia, anaemia and altered consciousness can also be signs of malaria 
infection (25). The erytherocytic cycle of P. falciparum becomes synchronized a few 
days after hepatocyte burst, and then fever occurs with 48h time intervals. These are the 
general characteristics of the disease, defining what is generally referred as 
“uncomplicated malaria”. This term is used to separate the more common, generally 
non-lethal forms of P. falciparum malaria, from “severe malaria”. If the 
“uncomplicated malaria” infection is not treated it can quickly develop into severe 
malaria and result in a fatal outcome 
 
Severe malaria is characterized by high parasite densities, above 200 000 parasites/µl. 
The symptoms of severe disease are unrousable coma, acute respiratory distress 
syndrome, severe anaemia, renal failure, cerebral malaria, metabolic acidosis, 
hypoglycemia splenomegaly and circulatory collapse.  
 
The mature stages (late trophozoites and schizonts) transform the RBC to a rigid and 
sticky cell which easily attach to the walls of the capillaries, also referred to as 
sequestration. The infected RBCs can also attach to other RBCs by a phenomenon 
called rosetting. Sequestered RBCs cannot be cleared by the spleen and can thereby 
avoid the immune system. This property of sequestration, unique to P. falciparum, can 
result in clogging of fine capillaries in for example the brain and lungs, giving rise to 
lethal conditions.   
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1.5 IMMUNITY 
Malaria is not a chronic disease. Individuals who live in stable transmission settings 
develop non-sterile immunity against malaria. During a child’s first months it is 
protected by antibodies from the mother (26). Then immunity towards severe disease 
develops during the first years in life, followed by immunity towards clinical symptoms 
of malaria. Older children and adults are less likely to develop severe disease but 
remain vulnerable to infection. The non-sterile immunity against malaria is only 
maintained if the individual continues to be exposed.  
 
It is still not known why immunity towards malaria develops so slowly. Recent 
evidence indicates that it is the interplay between different T cells, and the regulation of 
their response, throughout infection that influences immunity and pathogenesis of 
malaria. The immune response is context dependent, influenced by Plasmodium 
species, stage of the infection, and host factors (27). It was recently found that dendritic 
cells, highly specialized antigen-presenting cells, are reduced during malaria infection. 
Suggested that this might in part explain the slow and inefficient development of 
immunity to malaria infection (28). Due to the clear link between previous exposure to 
malaria and immunity development, there has been high hopes on vaccine 
development. The biggest challenge for vaccine development is the diversity of the P. 
falciparum. Both in terms of variation within the population and in terms of variation 
among the proteins displayed on the surface at any given time point.  
 
One peculiar and unfortunate feature of the malaria parasites is its ability to cause 
severe disease in pregnant women. Despite the woman being immune for many years, 
as soon as she becomes pregnant she is highly susceptible to get sick from malaria 
again. The risk is greatest during the first pregnancy and then gradually decreases for 
consecutive pregnancies (29). The increased susceptibly of pregnant women to malaria 
infection is thought to be caused be pregnancy associated immunological and hormonal 
changes as well as the presence of the placenta, a new niche for the parasite (30, 31). 
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1.6 CONTROL OF MALARIA 
Malaria has been eliminated (i.e. local transmission is completely stopped) in many 
parts of the world, like for example in Europe and US. In Sweden the last locally 
acquired malaria case was reported in 1930. These malaria elimination achievements 
were possible due to several factors such as; adequate treatment of sick patients, 
improved living conditions, removal of swampy areas. The mosquito that transmits 
malaria feeds only at night, therefore protecting humans from mosquito bites during 
night is an important tool for malaria control. Although these aspects are important also 
for elimination of malaria in still endemic countries there are several factors that make 
this task more difficult e.g. the climate and behaviour of the mosquito. Before 
elimination can be considered there has be sustainable malaria control.  
 
The tools currently used for malaria control are: 
 Prompt diagnosis and early effective chemotherapeutic treatment 
 Insecticide treated bed nets 
 Indoor residual spraying  
 Intermittent preventive treatment of risk groups 
 Larvicides 
 
The main focus of this thesis is chemotherapeutic treatment and this will be discussed 
further in the next section. However, in the following paragraph the other tools will be 
described in brief.  
 
Historically, the diagnosis for malaria was based only on symptoms with fever being 
the main symptom. Since fever is not exclusively a symptom of malaria, many patients 
have been given the wrong treatment and antimalarials have been grossly overused. 
Parasitological confirmation of the diagnosis of malaria before malaria treatment is 
started is recommended by WHO. Diagnosing malaria by using microscopy is still the 
gold standard but it is time consuming and requires well-trained staff. A major 
improvement therefore came when rapid diagnostic tests (RDTs) were introduced (e.g. 
in Tanzania in 2007). RDTs are fast and can be performed with very basic training. In 
stable high transmission settings WHO recommend the use of RDTs where high-
quality microscopy is not available. 
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The use of insecticide treated bed-nets is very important for malaria control and major 
achievements have been seen. From the year 2000 to 2011 the percentages of 
households, in sub-Saharan Africa, owning at least one insecticide treated net has 
increased from 3% to 50%. 
 
Indoor residual spraying is a method to kill mosquitos by spraying the inside walls of 
houses with insecticides. In 2009 the most used insecticide was pyrethroids accounting 
for approximately 77% of area sprayed, followed by dichlorodiphenyltrichloroethane 
(DDT) (~20% of areas sprayed). Due to resistance development towards pyrethroids, 
there is currently an on-going shift towards non- pyrethroids such as carbamates and 
organophosphates. 
 
Intermittent preventive treatment is prophylactic treatment recommended for risk 
groups such as pregnant women. Larvicides is an insecticide used to kill the mosquito 
larva stage.  
 
 
1.7 IMPORTANCE OF CHEMOTHERAPY FOR THE CONTROL OF 
MALARIA 
Chemotherapy is fundamental for malaria control. In Zanzibar, the number of malaria 
cases and deaths decreased dramatically after 2003 following wide scale deployment of 
antimalarial interventions (artemisinin combination therapies (ACTs), insecticide 
treated bed-nets and indoor residual spraying) (32). The main obstacles for malaria 
control today are the financial crisis, loss of immunity and resistance development 
towards antimalarial drugs and insecticides.  
 
 
1.8 DRUGS FOR MALARIA TREATMENT 
The first malaria treatments came from natural products that had proven to be effective 
against treatment of fever. For example, in 1735, Carolus Linnaeus described the 
antimalarial properties of bark from ash tree (ask in Swedish) (33). The major driving 
force for development of antimalarial drugs has been to protect military forces from 
malaria. This section will give an overview of the main drugs used for malaria 
treatment. 
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1.8.1 Quinolines 
All quinolines contain the quinoline ring structure (Fig. 2). There are two sub-classes of 
quinolines; the aminoquinolines and the aryl-amino alcohols.  
 
 
 
Figure 2. The quinoline ring structure 
 
 
1.8.1.1 The aminoquinolines 
The aminoquinolines are composed of 4-aminoquinolines (chloroquine, amodiaquine) 
and 8-aminoquinolines (primaquine). They are weak bases that are deprotonated and 
hydrophilic at neutral pH.  
 
Chloroquine (molecular weight: 319.872 g/mol) (RS)-N'-(7-chloroquinolin-4-yl)-N,N-
diethyl-pentane-1,4-diamine (Fig. 3), was developed in 1934 but came in clinical use 
first in 1945. Chloroquine is currently only used in areas where resistance has not 
developed e.g. Honduras. It is also used for treatment of P. vivax malaria in areas where 
chloroquine remains effective. 
 
Figure 3. The chemical structure of chloroquine 
 
 
Amodiaquine (molecular weight: 355.861 g/mol) g/mol4-[(7-chloroquinolin-4-
yl)amino]-2-[(diethylamino)methyl]phenol (Fig. 4), is structurally related to 
chloroquine and used as a partner drug in the artesunate-amodiaquine combination.  
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Figure 4. The chemical structure of amodiaquine (left) and its metabolite desethylamodiaquine 
(right) 
 
 
Primaquine (molecular weight: 259.347 g/mol) (RS)-N-(6-methoxyquinolin-8-
yl)pentane-1,4-diamine (Fig. 5), is an 8-aminoquinoline. It is recommended by WHO 
as anti-gametocyte treatment, especially in areas where pre-elimination or elimination 
is the target. It has also recently been recommended to be given in addition to ACT in 
areas threatened by artemisinin resistance  (34). Primaquine is however limited because 
of its associated risk of haemolysis in patients with G6PD deficiency. To prevent 
relapses of P. vivax, a 14-day treatment course of primaquine should always be used if 
the G6PD status allows it. 
 
 
Figure 5. The chemical structure of primaquine 
 
1.8.1.2 Arylamino alcohols 
Aryl amino alcohols are weak bases that are lipid soluble at neutral pH.  
 
Mefloquine (molecular weight: 378.312 g/mol) [(R*,S*)-2,8-
bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol (Fig. 6), is an 4-
methanolquinoline developed to save the lives of American solider during the Vietnam 
War. It is currently used as prophylaxis (Lariam
®
, F.Hoffmann-La Roche Ltd, Basel, 
Switzerland) and in combination with artesunate for treatment of uncomplicated 
malaria in South East Asia.  
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Figure 6. The chemical structure of mefloquine 
 
 
Quinine (molecular weight: 324.417 g/mol) (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-
8-vinylquinuclidin-2-yl)methanol (Fig. 7), was the first quinolone drug used for malaria 
treatment. Quinine came originally from the bark of the Cinchona tree (named by 
Carolus Linnaeus in 1742). It was used as a medicinal plant by tribes in Peru and 
Ecuador to treat fevers, its antimalarial effect was recognized in the XVII Century by 
the Spanish settlers and subsequently taken to Europe. Despite its long history as 
antimalarial, the therapeutic mechanism of quinine has not been fully resolved.  It is 
recommended as treatment of severe malaria. 
 
 
Figure 7. The chemical structure of quinine 
 
 
 
Lumefantrine (molecular weight: 528.939 g/mol) 2-(dibutylamino)-1-[(9Z)-2,7-
dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol (Fig. 8), is also an aryl 
amino alcohol and it is only available in combination with artemether. As lumefantrine 
is one of the main focuses of this thesis it will be descried more extensively in a 
separate section. 
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Figure 8. The chemical structure of lumefantrine 
 
 
1.8.2 Other drugs 
Piperaquine (molecular weight: 535.5 g/mol), 1,3-bis-[4-(7-chloroquinolyl-4)-
piperazinyl-1]-propane, 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-
yl]propyl] (Fig. 9), is a bisquinoline. It has been used in South East Asia as prophylaxis 
and is now used in combination with dihydroartemisinin (DHA) for treatment of 
uncomplicated malaria in both South East Asia and Africa.  
 
 
 
Figure 9.  The chemical structure of piperaquine 
 
 
Pyronaridine (molecular weight: 518.05 g/mol) 4-[(7-chloro-2-methoxy-pyrido[3,2-
b]quinolin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol (Fig. 10), is a 
benzonaphthyridine derivative first synthesized in China in 1970 and has been used 
there as monotherapy for treatment of malaria during 30 years (35). It has recently been 
combined with artesunate as a new combination therapy.  
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Figure 10. The chemical structure of pyronaridine 
 
 
1.8.3 Sesquiterpene lactones 
Artemisinin (molecular weight: 282.332 g/mol) (3R,5aS,6R,8aS,9R,12S,12aR)-
octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-
one (Fig. 11), is a class of drugs completely different from all other antimalarials.  
 
The artemisinin (qinghaosu) comes from the plan Artemisia annua L. (qinghao in 
Chinese, sweet wormwood in English, malört in Swedish) that has been used for at 
least the last 2000 years in China for treatment of fever. The project leading to the 
discovery of artemisinin was initiated in response to a request from North Vietnamese 
leaders, suffering heavily losses of soldiers’ lives due to malaria during the Vietnamese 
war (36). The Chinese leaders engaged to find solutions and in 1967 Chinese scientist 
started to screen Chinese herbs for antimalarial activity, and made extensive literature 
review. In Ge Hong's “A Handbook of Prescriptions for Emergencies” published in 341 
AD, they found the key notes that made them changes the recipe and thereby increased 
the effect of their best compound (37). In 1972, artemisinin was isolated and purified 
(38) and in 1979 the finding was announced (39)  
 
Artemisinin derivatives are used in all ACT combination therapies and for treatment of 
severe malaria. Due to their important role in this thesis they will be further described 
in a separate section. 
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Figure 11. The chemical structure of artemisinin, dihydroartemisinin, artemether, artesunate. 
  
 
1.8.4 Antifolates 
Antifolates is a class of drugs that interfere with the synthesis of folic acid. The two 
most common drugs within this class are sulfadoxine (molecular weight: 310.33 
g/mol) 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide and 
pyrimethamine (molecular weight: 248.71 g/mol) 5-(4-chlorophenyl)-6-ethyl- 2,4-
pyrimidinediamine (Fig. 12) which are used in combination. Sulfadoxine-
pyrimethamine is currently used for intermittent preventive treatment of pregnant 
women and as malaria treatment for pregnant women in the first trimester.  There is 
also a combination therapy with sulfadoxine-pyrimethamine and artesunate.  
 
 
 
Figure 12. The chemical structure of pyrimethamine (left) and sulfadoxine (right) 
 
 
1.8.5 Artemisinin combination therapy 
According to the 2
nd
 edition of the WHO Guidelines for the treatment of malaria 
published in March 2010, ACT is globally the recommended treatment for 
uncomplicated P. falciparum malaria (40). 
 
The basic principle behind ACT is to improve drug efficacy of the artemisinin 
derivatives by combining it with an effective partner drug that can kill off the 
remaining parasites (41). This scenario markedly reduces the amount of parasites that 
remains for the partner drug as compared to if the partner drug were to be used as 
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monotherapy (Fig. 13). The two drugs combined should have independent modes of 
action and thereby prevent or at least delay the emergence of resistance. If a mutation 
associated with resistance to one of the drugs arises de novo in one parasite during the 
treatment, this resistant parasite will be killed by the other drug.  The pharmacokinetic 
profiles of the two drugs should ideally be matched, so that both drugs protect each 
other during the full treatment. Due to the very short half-life of the artemisinin 
derivatives, the pharmacokinetic profiles of all currently used ACTs are not matched.  
 
 
Figure 13. The principle behind ACT treatment with artemether-lumefantrine as the example. The 
large triangle under the blue line represents the total parasite biomass when exposed to a lumefantrine 
in monotherapy. In ACT, the artemisinin derivative rapidly reduces the parasite biomass (green line) 
and only a small number of residual parasites (turquoise triangle) will be exposed to lumefantrine. 
These parasites meet a much higher concentration of lumefantrine (area under orange curve) than the 
same parasite biomass exposed to lumefantrine in monotherapy (purple triangle). Adapted from (White 
et al. 1997)(42) 
 
There are presently five ACTs approved by WHO; artemether-lumefantrine, 
artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-
pyrimethamine and dihydroartemisinin-piperaquine. The most recent ACT, 
pyronaridine-artesunate is yet only approved by the European Medicines Agency. 
 
 
1.8.6 Counterfeit and substandard drugs 
The use of counterfeit and substandard drugs is a major problem and it has been 
estimated that up to 35% of the antimalarials in sub-Saharan Africa are substandard 
(43). Counterfeit drugs can contain too low quantities of the active substance, 
potentially leading to resistance selection. Considering the artemisinins importance in 
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the first hours of therapy, the use of such substandard medicines can have serious 
consequences. In sub-Saharan Africa in 2002, WHO estimated there to be a traditional 
medicine practitioner per 500 people, and only one regular medicine practitioner per 
40 000 people (44). There is a risk that counterfeit and substandard drugs would reduce 
the public’s confidence in medicines and modern health care and make people turn to 
traditional medicine. This could result in reduced intake of potentially life-saving 
medicines (45).  
 
 
1.9 MALARIA IN TANZANIA 
United Republic of Tanzania constitutes of mainland Tanzania and Zanzibar. The focus 
of this thesis will be on mainland Tanzania, situated in East Africa. In 2009, the 
population of United Republic of Tanzania was 43.7 million, out of which 45% were 0-
14 years old. The average birth rate was 5.3 children per woman. The life expectancy at 
birth was 59 years for women and 57 years for men (46).  
 
In Tanzania, 73% of the population lives in areas with high malaria transmission, 
defined as ≥1 case per 1000 population. More than 40% of all outpatient visits are 
attributed to malaria and the number of annual malaria deaths is estimated to be 60 000 
(47). Indoor residual spraying is recommended since 2006, intermittent preventive 
treatment for pregnant women was adopted in 2001. In 2004 artemether-lumefantrine 
(Coartem
®
, Novartis Pharma AG, Basel, Switzerland) (Fig. 14) was adopted as first 
line treatment of uncomplicated malaria, having been implemented throughout the 
country in the subsequent years. In Bagamoyo district, coastal Tanzania, it was 
implemented late 2006 (48). Quinine was adopted 2004 as treatment of severe malaria 
(4). 
 
 
1.10 ARTEMETHER-LUMEFANTRINE 
Artemether-lumefantrine is highly effective ACT with PCR adjusted cure rates 
exceeding 95% in 16 out of 22 studies in the latest Cochrane review (49). In 2001, 
Novartis agreed to make artemether-lumefantrine available without profit for 
distribution through the WHO to malaria-endemic developing countries. Since 2001, 
over 500 million treatments of artemether-lumefantrine have been delivered to more 
than 60 endemic countries. Artemether-lumefantrine is currently the most widely used 
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antimalarial, approved in 86 countries. In Africa 30 out of 47 countries have adopted 
artemether-lumefantrine as first line treatment, and an additional eight as second line 
treatment (50).  
 
 
Figure 14. Coartem
®
 Dispersible (artemether-lumefantrine).  
Printed with permission from Erik Larsson 
 
 
1.11 ARTEMETHER AND DIHYDROARTEMISININ 
From the firstly discovered compound artemisinin, several derivatives have been made 
such as; artemether, artesunate, arteeter, DHA etc. (Fig. 11). Artemether is the 
artemisinin derivative in artemether-lumefantrine and therefore this section will focus 
specifically on it and its active metabolite DHA. 
 
1.11.1 Pharmacokinetics of artemether and dihydroartemisinin 
Artemether is quickly absorbed, reaching peak plasma concentrations ~2h after tablet 
ingestion (41, 51). The absorption of artemether is increased by food intake (41). When 
artemether reaches the liver it is rapidly and extensively metabolised by demethylation 
into dihydroartemisinin.  
 
During the distribution phase, artemether and dihydroartemisinin binds readily to 
human serum proteins (95.4% and 47-76%, respectively) (52). In patients infected with 
malaria, 93% of DHA was found to be protein bound (53). Both artemether and DHA 
are rapidly cleared from plasma with an elimination half-life of about 1-3h (41, 51). 
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Artemether is mainly metalized to DHA via first-pass metabolism by enzymes belong 
to the cytochrome P450 enzyme (CYP) superfamily. The main actor is the CYP3A4, 
with possible contribution of CYP1A2 and CYP2B6 (54, 55) and CYP3A5 (Rita 
Piedade, personal communication). Artemisinins have auto inducing properties 
resulting in reducing concentrations for each dose (56). Artemether and DHA have 
been reported to have an inducing effect on CYP3A4 and CYP2B6 activity which 
results in increased levels of artemether being metabolized after each consecutive dose 
(57). The induction is driven by nuclear receptors. 
 
 
1.11.2 Pharmacodynamics of artemether and dihydroartemisinin 
The artemisinin component has a parasite reduction rate of 1:10 000, i.e. within 48 
hours after in vivo treatment the parasitaemia has decrease by 99.99% (42). It is the 
fastest acting antimalarial ever developed and it is active against a broad range of stages 
within the malaria parasite life cycle. It is believed to be able to kill also the sexual 
stage to of the malaria parasite, the gametocytes (58), which is generally not true for 
other antimalarials. Artemisinin compounds are also active on the sequestered stages, 
which make them particularly useful to treat severe malaria (59). Accordingly, since 
April 2011, WHO recommends artesunate for treatment of severe malaria (60). The 
rapid elimination of artemisinin derivatives is advantageous as it theoretically limits the 
parasites ability to develop resistance due to reduced time of exposure. However the 
fast elimination represents a disadvantage as it limits the capacity of these compounds 
to clear the total parasite burden. Accordingly, recrudescences (i.e. treatment failure) 
are seen in ~10% of the patients after seven days of artesunate monotherapy (61) . To 
make the treatment more efficient and to protect the artemisinins derivative from 
resistance development, WHO presently recommends for these compounds to be used 
only in combination with a partner drug for the treatment of uncomplicated malaria.  
 
In general, artemisinin derivatives are well tolerated at the presently prescribed doses. 
There has been concerns with neurotoxicity, especially in the first trimester of pregnant 
women (62, 63) Studies where increased dosing of artesunate from the standard 4mg/kg 
to 6mg/kg reported neutropenia in 19% suggesting that the maximum dose limit of 
artesunate has already been reached (64).  
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1.11.3 Artemether and dihydroartemisinin – mechanism of action 
For the artemisinin derivatives, the mechanism of action is not known. It is known that 
artemisinin compounds are concentrated in the parasite infected RBCs. In vitro 
experiments have shown that DHA concentrations in infected RBCs are 300 times 
higher than in the medium, whereas uninfected RBCs had a less than two-fold increase 
as compared to the medium (65). Most studies agree that the peroxide bridge of the 
artemisinins is essential for antimalarial activity. There are several hypotheses as to 
how artemisinins exert its action.  
 
 Interferences with haem-detoxification  
 Induction of alkylation of translationally controlled tumor proteins(66) 
 Inhibition of sarco/endoplasmic reticulum membrane calcium transporting 
ATPase6 (67) 
 Interference with mitochondrial function 
 
One theory hypothesise that the activity of artemisinin and its derivatives results from 
reductive scission of the peroxide bridge by reduced haem iron  inside the highly acidic 
digestive vacuole (68). This theory was supported by a recent study where fluorescent 
artemisinin trioxane derivatives provided evidence for their rapid accumulation in the 
digestive vacuole and their activation by neutral lipid-associated haem (69). It has 
recently been shown that artesunate can inhibit haemozoin formation (70).  
 
 
1.12 LUMEFANTRINE 
Lumefantrine, previously known as benflumetol is a highly lipophilic compound (Fig. 
8). It is an aryl-amino-alcohol structurally related to mefloquine, halofantrine and 
quinine. 
 
 
1.12.1 Pharmacokinetics of lumefantrine 
Absorption of lumefantrine starts after a lag-phase of up to 2h and peak plasma 
concentrations are reached first 6-8h after tablet taken (71). To get the maximum 
lumefantrine absorption it is recommended that artemether-lumefantrine is taken 
together with food or drink (41, 71, 72). It has been suggested that the fat content in 
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standard African diet or breast milk is enough to ensure optimal absorption (73). 
Lumefantrine is highly bound to human serum proteins (99.7%).  
 
Elimination of lumefantrine is much slower than that of artemether and DHA. 
Lumefantrine has a terminal elimination half-life of 3-5 days (71, 74, 75). This results 
in a gradual increase in lumefantrine plasma concentrations throughout the three day 
artemether- lumefantrine treatment course (41, 51).  
 
Lumefantrine is N-butylated, mainly by CYP3A4 (54). It is however only a small 
fraction (~1%) of lumefantrine that becomes the metabolite desbutyl-lumefantrine.  
 
 
1.12.2 Pharmacodynamics of lumefantrine 
When lumefantrine was introduced on the market it was as a combination therapy with 
artemether, therefore not much data exist on the pharmacodynamics effects of 
lumefantrine alone. 
 
 
1.12.3 Lumefantrine – mechanism of action 
The mechanism of action of lumefantrine is not fully elucidated. It was recently shown 
that lumefantrine inhibits haemozoin formation in the parasite cell, suggesting that 
lumefantrine similarly to chloroquine, interfere with the haemoglobin detoxification 
process within the digestive vacuole (70). This might be one but most probably not the 
only mechanism of action of lumefantrine. 
 
 
1.13 ANTIMALARIAL DRUG RESISTANCE 
As with other infectious diseases drug resistance is a major obstacle in the treatment 
and control of malaria. In general, whenever an antimalarial drug has been used for 
longer periods, resistance develops. This severely limits our ability to control this 
disease, with consequences not only directly in public health, but also as substantial 
economic costs.  
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1.13.1 Drug resistance and tolerance 
WHO defines antimalarial drug resistance as “the ability of a parasite species to survive 
and/or to multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended but within the limits of tolerance of 
the subject” (WHO, 1973). In 1986 the definition was clarified with the addition of “the 
form of the drug active against the parasite must be able to gain access to the parasite or 
the red blood cell for the duration of time needed for its normal action”.  
 
Concerning drugs with expected multiple targets and pleiotropic effects, development 
of resistance is most likely a process not involving an on/off event, but rather an 
ongoing progression of stepwise increased changes leading initially to tolerance. 
Tolerant parasites are killed by the high drug levels achieved during the initial phase of 
treatment but can withstand higher levels than fully sensitive parasites. In clinical, real 
world terms, it means that although the action of the drug on these parasites is still 
inside the therapeutic window and hence being still cleared by the usual therapeutic 
doses, this reduced sensitivity will position these parasites nearer the top of this 
window. The parasites are still “clinically invisible”, but represent populations probably 
developing towards a fully resistant phenotype. 
 
This has implications in the post-treatment prophylactic period after ACT treatment. 
The ACT partner drugs have long half-lives and remain in the individual for weeks or 
up to months, providing the reoccurring parasites with a gradient of decreasing 
concentrations. During this window of selection it is possible to study tolerance 
development acquired through accumulation of favourable mutation and/or other 
modifications (76, 77). Usually these mutations are associated with a fitness cost, 
deeming them advantageous only in the presence of drug (78, 79).  
 
 
1.13.2 Mechanisms of drug resistance 
There are different ways for the malaria parasite to develop drug resistance. Without 
going into specific details the overall mechanisms are: 
 Avoid drug-target interaction  
- By alteration of intracellular drug levels (e.g. decreased uptake, increased 
export, inactivation by metabolism or sequestration) 
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- By alteration of the drugs ability to affect the target (e.g. decreased target 
affinity for the drug of complete loss of target) 
 Dormancy 
 Overexpression of systems to handle indirect drug effects. 
 
 
1.13.3 History of antimalarial drug resistance 
Chloroquine was introduced in 1945 and became the first global chemotherapy for the 
control of malaria. Although extremely effective for near one decade, the first cases of 
clinical resistance to the drug emerged in 1958-1959 in the Thailand/Burma border and 
in remote provinces in Colombia and Venezuela (80), and later on spread globally. 
New drugs like the antifolate drug combination sulfadoxine-pyrimethamine and the 
synthetic quinoline derivative mefloquine were introduced during the 1960s and 1970s 
as an attempt to control the disease. Unfortunately, resistance to both drugs developed 
within less than five years (81-83). These observations and their clinical consequences 
are clear indications of the strong capacity of the parasite to adapt to new drug 
challenges. In this context, a common measure to delay the development of drug 
resistance is the introduction of combinations of drugs. A measure used since long for 
treatment of HIV/AIDS and tuberculosis.  
 
 
1.13.4 Methods to assess antimalarial drug resistance 
Antimalarial drug resistance can be assessed using different methods, i.e. in vivo 
(treatment failure in clinical trials), ex vivo (drug assays directly on blood from the 
patients, also referred to as “micro tests”), in vitro (parasites susceptibility to drugs in 
laboratory culture) or by analysis of molecular markers associated with drug resistance. 
There are advantages and disadvantages with each of these methods.  
 
The way to evaluate drug efficacy in vivo is based on a 28 or 42-day test (84), where 
the patient’s clinical and parasitological response is classified into “early treatment 
failure”, “late clinical failure”, “late parasitological failure”, or “adequate clinical and 
parasitological response” (ACPR). The major limitation with this test for evaluation of 
therapeutic efficacy is that resistance may not always be detected, due to for example 
pharmacokinetic variation, re-infections, multiple infections, non-compliance or 
interference with the acquired immune response. There have been suggestions to 
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improve the definition by include for example in vitro tests, and measured drug 
concentrations to assure that treatment failure is not due to inadequate levels if drug 
(85).  
 
Ex vivo methods have the advantage that they are applied to the actual parasites from 
the patient, and are possible to standardize. The disadvantages are that there could be 
influences from the immune system of the patient, minority clones could be lost due to 
lack of fitness, and the method requires well-trained personnel.  
 
In vitro methods have the advantage that they are independent of the patient’s 
immunity, can be performed in a controlled environment, repeated and used to test 
different drugs. The limitation are that some aspects of the parasite might be lost during 
long term adaptation to ideal conditions, the methodology is very costly and time 
consuming and require very well-trained personnel and advance laboratory facilities.  
 
1.13.4.1 Molecular surveillance 
Surveillance of molecular markers associated with drug resistance is a way to estimate 
drug efficacy. Genetic markers from a sub-set of the population are expected to reflect 
the prevalences of these single nucleotide polymorphisms (SNPs) in the total parasite 
population. For example, if molecular makers that accurately predict treatment failure 
are available these can be used for molecular surveillance and further on guide 
authorities in decisions regarding drug policies. Unfortunately, it is difficult to define 
biomarker with clinical value. It demands in general detailed knowledge not only of the 
mechanisms of action of the drug and resistance against it, but also of the drugs 
pharmacokinetic and pharmacodynamics characteristics. Due to this multi-factorial 
aspect of the clinical definition of resistance, no molecular marker is presently available 
with levels of specificity and sensitivity compatible with the demands of replacing 
phenotype determinations of resistance. Further studies in the several above mentioned 
aspects are needed, as such tool is, no matter the challenge, a fundamental factor for the 
ongoing malaria elimination plans. 
 
A large advantage with molecular marker based surveillance as compared with the 
much more resource consuming drug efficacy clinical trials is that it is possible to scale 
up and feasible also when the patient population is small and time is scattered.   
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1.13.5 Artemisinin resistance 
Due to its characteristic very short half-life and the rapid “pulse”- like exposures, it was 
originally thought that the malaria parasite would not be able to develop resistance 
towards artemisinin derivatives. To detect artemisinin resistance it is recommended to 
perform artesunate monotherapy clinical trials to avoid the influence of partner drugs.  
 
It has been proposed that a clinical case of artemisinin resistance would have to fulfil 
all of the following criteria (86): a) persistence of parasites at seven days after the start 
of monotherapy with artemisinin compounds, or re-emergence of parasites within 28 
days after the start of treatment; b) adequate plasma concentrations of DHA; c) 
prolonged parasite clearance time; and d) reduced in vitro susceptibility of the parasite.  
 
The first reports on artemisinin resistance, as defined by the above mentioned criteria’s 
came from the Thai-Cambodian border (87, 88). Thereafter there have been several 
reports of patients with prolonged parasite clearance time from; Thai-Burma border 
(89), Pursat region in Cambodia (90) , Vietnam (91) and Pailin in Cambodia (92). None 
of these reports have however fulfilled all the criteria’s of artemisinin resistance. There 
in an ongoing controversies regarding whether only prolonged parasite clearance can be 
called artemisinin resistance and what the consequences of these findings are (93, 94). 
 
Formally, artemisinin resistance is currently assessed as either: 
 Suspected resistance: Microscopically confirmed positivity day 3 after ACT 
treatment (if ≥10%, containment activities should begin immediately),  
Or 
 Confirmed resistance: Treatment failure after treatment with an oral 
artemisinin-based monotherapy , as evident by persisting parasites day 7, or the 
presence of parasites day 3 and recrudescence within 28/42 days (adequate 
antimalarial blood concentrations confirmed)(91) 
 
Anyway, the finding of artemisinin resistant parasites and the prolonged parasite 
clearance times are worrying. Artemisinin derivatives are basis of all ACTs, therefore 
the consequences of spread of resistance to these compounds should not be 
underestimated. After the identification of the South East Asia foci of suspected 
artemisinin resistance, strategies have been implemented to contain the spread of these 
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parasites. Unfortunately, it is becoming clear that these actions have not been 
sufficiently effective to halt its expansion (95). 
 
The delayed parasite clearance phenotype has been proposed to have a genetic 
component (96). Accordingly, a major region on chromosome 13 has been identified to 
explain 35% of the slow clearance phenotype (97), although no molecular markers are 
yet available. It has been proposed that the observed delayed parasite clearance time is 
explained by reduced sensitivity in particularly the ring stage (98, 99). This view was 
anyway not supported by a clinical trial designed for the administration of a split dose 
of artesunate, which showed no improvement on parasite clearance rates (100).There 
have also been reports on dormancy, which could potentially explain the phenotype 
observed (99, 101). 
 
 
1.14 RESISTANCE ASSOCIATED GENES 
 
1.14.1 Plasmodium falciparum multidrug resistance gene 1 (pfmdr1) 
The P. falciparum multidrug resistance gene 1 (pfmdr1) codes for a transmembrane 
protein (PfMDR1) belonging to the ATP-Binding Cassette (ABC)-transporter 
superfamily. The protein is located in the digestive vacuole membrane and to a minor 
extent in the plasma membrane (102-104). In the digestive vacuole the PfMDR1 is 
believed to be faced towards the digestive vacuole, able to import molecules, including 
some antimalarial drugs, into the lumen of the digestive vacuole (105, 106).  
 
Chloroquine resistance was early proposed to be based on the efflux of the drug from 
the parasite (107). These reports were later supported by several groups, further adding 
the observation that this was reversible by the calcium blocker verapamil (108, 109) . 
The same verapamil sensitization effect had been previously documented in resistant 
cancer cells, associated with the action of the efflux pump P-glycoprotein. Driven by 
this knowledge the search for the P. falciparum P-glycoprotein homologue started. Two 
genes were identified and named pfmdr1 and pfmdr2 (110, 111). The pfmdr1 proved 
the best candidate to be associated with antimalarial drug resistance. Upon its 
discovery, promising initial associations between in vitro chloroquine resistance in 
adapted parasite clones and the presence of specific pfmdr1 SNPs (112) were reported. 
These were rapidly dismissed by the discovery that the main genetic factor was actually 
   27 
located in a different chromosome (113), as well as the frequent lack of association 
between clinical failure and the presence of these mutations (114, 115). Presently, 
pfmdr1 is believed to represent a secondary – but non negligible - factor in the 
mechanism of chloroquine susceptibility. 
 
Nevertheless, the pfmdr1 gene has been found to be pivotal in the parasite response to 
presently more relevant antimalarials. The main SNPs found in pfmdr1 are N86Y (N = 
asparagine, Y = tyrosine), Y184F (F = phenylalanine), S1034C (S = serine, C = 
cysteine), N1042D (D = aspartic acid), and D1246Y (110). SNPs in pfmdr1 have been 
associated in vivo and in vitro with reduced susceptibility to important ACT drugs such 
as mefloquine (116-119), lumefantrine (77, 120), amodiaquine (121, 122) and 
artemisinin (117, 118, 123, 124). 
 
In vivo, the pfmdr1 has been shown to select for N86, 184F, D1246 among re-infections 
upon artemether-lumefantrine treatment (77, 120, 125, 126). This was further supported 
by culture adapted Kenyan isolates where isolates with pfmdr1 N86 had significantly 
higher lumefantrine IC50 values as compared to the 86Y (127). Recently, a newly 
identified polymorphism in the pfmdr1, i.e. 1226Y, was correlated with reduced 
artemisinin, lumefantrine and mefloquine response in culture adapted field isolates 
from Thailand (128).  
 
Duplications of the pfmdr1 gene have been associated with decreased in vitro 
susceptibility to mefloquine, quinine and halofantrine (129, 130). In vitro development 
of mefloquine resistance has been shown to be associated with increased pfmdr1 copy 
number (130-132). Knock down experiment removing one of the two copies of pfmdr1 
in the clone FCB, resulted in increased sensitivity to quinine, lumefantrine, mefloquine, 
artemisinin and halofantrine (133). These in vitro findings have been confirmed in vivo 
in mefloquine, artesunate-mefloquine and four dose artemether-lumefantrine clinical 
trial where increased pfmdr1 copy number have been associated with treatment failure 
(116, 134, 135). All these in vivo findings are from South East Asia, where duplications 
of pfmdr1 are frequently found, however presently pfmdr1 duplications seem to be 
essentially non-existent on the African continent (120, 136, 137).  
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1.14.2 Plasmodium falciparum chloroquine transporter gene (pfcrt) 
The pfcrt (P. falciparum chloroquine resistance transporter) gene has been found to 
play a central role in chloroquine resistance. It codes for a transmembrane protein 
PfCRT, located in the digestive vacuole membrane, the compartment where 
haemoglobin (the parasites main amino acid source) is degraded and detoxified. It is 
currently not known how di-peptides generated from haemoglobin degradation are 
transported from the digestive vacuole to the cytoplasm. However, recent work using 
parasites from a genetic cross between a chloroquine resistant and a chloroquine 
sensitive strain, combined with a metabolomic approach, showed an accumulation of 
di-peptides in chloroquine resistant parasites (Manuel Llinás, personal communication). 
These results suggest that PfCRT, a member of the drug/metabolite transport 
superfamily, may be involved directly or indirectly in the transport of di-peptides (138).  
 
Through accumulations of SNPs the PfCRT is capable of transporting chloroquine out 
of the digestive vacuole (139, 140). The SNP that is most strongly associated with 
chloroquine resistance is located on codon 76, where a lysine (K) in replaced by a 
threonine (T) (141, 142).  Currently, the most accepted hypothesis for chloroquine 
mode of action is by the drugs capacity to  interfere with the process of detoxification 
of haem inside the digestive vacuole, namely its polymerization to haemozoin (70). The 
76T harbouring PfCRT is hence able to decrease chloroquine concentration in the 
digestive vacuole, where the drug acts. On the contrary, the parasites harboring PfCRT 
carrying the K76 allele are unable (or at least, less able) to efflux the drug (143), 
rendering the parasite more susceptible.  
 
Besides its role in chloroquine resistance, allele exchange experiments have clearly 
shown that PfCRT is potentially involved in the parasite’s response to other 
antimalarials (142, 144, 145). Specifically in the ACT context, this gene might also 
play a role in resistance towards artemether-lumefantrine. It has been shown that the 
pfcrt K76 is selected among re-infection after artemether-lumefantrine treatment (146), 
an observation supported by in vitro works pointing for the K76 to be associated with 
reduced susceptibility to lumefantrine (127, 146). 
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1.14.3 Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) 
The pfmrp1 gene codes for an ABC-transporter (PfMRP1) located in the parasites 
plasma suggested to act as a GSH/GSSG pump (147) and drug effluxer (148, 149). This 
hypothesis has recently been supported by the in vitro finding that parasites with 
disrupted PfMRP1 accumulate GSH (reduced glutathione), GSSG (oxidized 
glutathione) and GSH-conjugates. The disruption also resulted in an accumulation of 
chloroquine and quinine, and reduced susceptibility to piperaquine, primaquine, 
artemisinin as well as chloroquine and quinine (150).  
 
A significant association of parasites harbouring PfMRP1 carrying the 1390I (I = 
isoleucine) allele with reduced susceptibility to lumefantrine, artemisinin and 
mefloquine have been seen in culture adapter clones from the Thai-Burma border 
(128). In clinical trials a significant selection of parasites carrying the PfMRP1 I876 
allele has been seen among recurrent infections upon artemether-lumefantrine treatment 
(151) and the PfMRP1 K1466 allele has been shown to be selected within 
recrudescences after sulfadoxine-pyrimethamine treatment (152).  
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2 SCOPE OF THE THESIS 
 
The overall aim of this thesis was to contribute to the understanding the molecular basis 
of emerging artemether-lumefantrine resistant P. falciparum. 
 
The specific aims of the different studies were: 
 
Paper I 
 To investigate how well artemether-lumefantrine is working in real life and 
under ideal conditions and how this relates to whole blood day 7 lumefantrine 
concentrations.  
 To assess if treatment with artemether-lumefantrine selects for genetically 
distinct parasite populations among recurrent infections, with focus on the 
major drug resistance associated genes pfmdr1 and pfcrt. 
 
Paper II 
 To examine if selection of pfmdr1 SNPs among re-infections after artemether-
lumefantrine treatment is associated with lumefantrine drug concentrations.   
 To assess the relative importance of different SNPs for the parasites capacity to 
withstand lumefantrine in vivo. 
 
Paper III 
 To analyse temporal trends of the prevalence of pfmdr1 and pfcrt SNPs after the 
implementation of artemether-lumefantrine as first line treatment for 
uncomplicated malaria in Tanzania. 
 
Paper IV 
 To assess if artemether/dihydroartemisinin in vivo select for the same molecular 
markers as lumefantrine.  
 To examine the characteristics of the lumefantrine window of pfmdr1 and pfcrt 
SNP selection after artemether-lumefantrine treatment. 
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3 MATERIAL AND METHODS 
 
 
3.1 STUDY LOCATION AND POPULATION 
All studies included in this thesis were conducted in coastal region of mainland 
Tanzania from the year 2004 to 2011. The primary study site was Fukayosi dispensary 
in Bagamoyo District (Fig. 15). Studies were also conducted in Yombo, Bagamoyo 
District and in Ngeta and Mwanabwito villages, Kibaha district.  
 
 
Figure 15. The Fukayosi dispensary, Bagamoyo District, Tanzania.   
Printed with permission from Erik Larsson.   
 
The area were the studies were conducted is primarily rural. Malaria transmission is 
high and occurs throughout the year with some accentuation during the rainy seasons in 
May–July and to a lesser extent between December-January. P. falciparum is the 
predominant malaria species and Anopheles gambiae complex the main vector. 
 
Study participants were recruited among patients presenting at the study sites for 
routine care. All patients included in the studies were children ≤10 years with 
uncomplicated microscopy confirmed P. falciparum infection.  
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3.2 CLINICAL STUDIES  
The clinical trials analysed in this thesis where conducted in accordance with WHO 
recommendations. Blood samples were collected on filter paper at day of inclusion and 
for studies with follow up at the pre-determined days of re-visit as well as at any day 
when the patient felt sick. 
 
The MIM/TDR (Multilateral Initiative on Malaria / Research & Training in 
Tropical Diseases) study (n=359): was a two arm (efficacy versus effectiveness) 
randomized, open-label, parallel-group, controlled artemether-lumefantrine clinical trial 
conducted in 2007-2008 in the villages Fukayosi and Yombo, Bagamoyo district (136). 
The drugs intake was provided under supervision in the efficacy arm whereas patients 
and parents/guardians in the effectiveness arm were informed to take the drug at home. 
The complete analysis of this study is presented in Paper I. In Paper II, the first follow 
up of 56 days from this study is included. In Paper III the part of this study that was 
conducted in Fukayosi (n=258) is referred to as Study 3 (Fig. 16).  
 
The CCC (Coartem to Children at Community level) study (n=244): was a single 
arm effectiveness artemether-lumefantrine clinical trial conducted in 2007 in the Ngeta 
and Mwanabwito villages, Kibaha district (153). This study was included in Paper II. 
 
The Fukayosi I study (n=106): was a two arm (artemether-lumefantrine versus 
sulfadoxine-pyrimethamine) efficacy trial conducted in 2004 at Fukayosi dispensary, 
Bagamoyo district (146, 154). It is referred to as Study 1 in Paper III.  
 
The Fukayosi II study (n=50): was an artemether-lumefantrine pharmacokinetic and 
pharmacodynamics study performed in 2006 at Fukayosi dispensary, Bagamoyo district 
(75, 155) . It is referred to as Study 2 in Paper III. 
 
The Fukayosi IV study (n=200): was a pre-treatment blood sampling done in 2008 at 
Fukayosi dispensary, Bagamoyo district. It is referred to as Study 4 in Paper III. 
 
The Fukayosi V study (n=33): was a pre-treatment blood sampling done in 2010 at 
Fukayosi dispensary, Bagamoyo district. It is referred to as Study 5 in Paper III. 
 
The Fukayosi VI study (n=130): was a pre-treatment blood sampling done in 2011 at 
Fukayosi dispensary, Bagamoyo district. It is referred to as Study 6 in Paper III. 
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Figure 16. An overview of the clinical studies and the papers that they appear in.  
 
3.3 TREATMENT 
All patients included in the studies received a three day treatment with artemether-
lumefantrine. The six doses were taken at 0h, 8h, 24h, 36h, 48h and 60h. The tablets 
contained 20 mg artemether and 120 mg lumefantrine and were administered based on 
weight; 1 tablet (5–14 kg), 2 tablets (15–24 kg), 3 tables (25-34 kg). 
 
 
3.4 DNA EXTRACTION 
Blood samples from patients were collected on filter paper (3MM; Whatman) and 
transferred to Karolinska Institutet, Stockholm, Sweden. Genomic DNA was extracted 
from the blood spots using the BloodPrep
TM
 Chemistry on an ABI PRISM
®
 6100 
Nucleic Acid PrepStation (Applied Biosystems, Fresno, CA, USA) according to the 
manufacturer’s instructions. Day 3 samples included in Paper IV were extracted using a 
modified Chelex extraction protocol (156). 
 
 
3.5 MOLECULAR ANALYSIS 
 
3.5.1 PCR-Restriction Fragment Length Polymorphism (RFLP) 
PCR-RFLP is an old method based on the use of restriction enzymes to differentiate 
between SNPs. Restriction enzymes has the capacity to cut DNA at a very specific 
Fukayosi I 
Fukayosi IV 
MIM/TDR  
MIM/TDR  
Paper III 
Paper I 
Paper II 
Paper IV MIM/TDR  
Fukayosi II 
Fukayosi V Fukayosi VI 
MIM/TDR  
CCC 
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sequence pattern. The presence of a SNP will be detected trough the different sizes of 
fragments as result of the restriction. In this thesis the pfmdr1 N86Y, pfmdr1 Y184F 
pfmdr1 D1246Y and pfcrt K76T SNPs were analysed by PCR-RFLP. 
 
 
3.5.2 Pyrosequencing 
Pyrosequencing was developed by Pål Nyrén and Mostafa Ronaghi at the Royal 
Institute of Technology, Stockholm in 1996 (157). The technology relies on detection 
of pyrophosphate release upon nucleotide incorporation and is used to sequence short 
DNA fragments. This technology has been suggested to be particularly useful in 
malaria research as it can reliable detect mixed infections. In high transmission settings 
it is very common that patients are infected by more than one genetically distinct 
population of P. falciparum parasites, also referred to as multiplicity of infections. As 
the malaria parasite is haploid during its stay in the human host all possible proportions 
of allele distribution can be found within mixed infections (Zhou et al 2006).  
 
In this thesis the pfmdr1 Y184F, pfmdr1 D1246Y, pfmdr1 F1226Y, pfmrp1 F1390I 
SNPs were analysed by pyrosequencing PyroMark™ ID instrument (Qiagen, 
Germany). Serial dilutions of different proportions of mutant and wild type alleles 
originating from laboratory clones were used to determine the cut-off for mixed 
infections. The definition of mixed infections was all samples with more than 10% of 
each allele at a particular locus.  
 
 
3.5.3 Sequencing 
DNA sequencing can provide data on the full DNA sequence for bigger fragments (i.e. 
up to ~700bp) and is therefore preferable when your interest is on a more than one 
SNP. The DNA sequencing was outsourced (Macrogen Inc, Seoul, South Korea). 
 
In this thesis the pfmdr1 N86Y, pfmdr1 Y184F, pfmdr1 D1246Y SNPs and the regions 
around them were analysed by sequencing.  
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3.5.4 Real Time PCR 
Real Time PCR has the advantage of being faster than conventional PCR and is 
particularly useful for detection of copy number variation. The pfmdr1 gene copy 
number was assessed through TaqMan  probe based quantitative real time PCR (ABI 
Prism  7000 Sequence Detection System) (116). (158). To be able to make relative 
quantification two probes were used, one targeted the β-tubulin gene, known to be 
present in only one copy, the other probe targeted our gene of interest pfmdr1. In each 
experiment three P. falciparum clones with only one copy of pfmdr1 were used as 
calibrators and two clones with more than one copy of pfmdr1 were used as positive 
controls. 
 
Using the so called “∆∆Ct method” (159) we calculated the copy number in accordance 
with modifications made in previous work (116) and a copy number > 1.5 was defined 
as an amplification of pfmdr1.  
 
In this thesis pfmdr1 copy number was assessed in Paper I and in Paper III.  
 
3.5.5 Distinguish between re-infection and recrudescence 
When efficacy of antimalarial drugs is evaluated using clinical trials, it is quite 
common, in particular in high transmission settings that patients get a recurrent P. 
falciparum infection. As these infections can be due to a new infection (i.e. re-
infection) or a recrudescence (i.e. treatment failure), it is very important to be able to 
distinguish between these two types. This is done by comparing the infection at 
baseline and with the recurrent infection, using nested PCR. For this three highly 
polymorphic genes P. falciparum merozoite surface protein 2 (msp2) and 1 (msp1), and 
glutamate-rich protein (glurp) are used (160).  
 
By using nested PCR, distinction between recrudescence and re-infection was 
performed by stepwise genotyping of the msp2 and msp1, and glurp according to 
previously described protocols (161).  Recrudescences were defined as samples 
containing at least one matching allelic band in all markers between baseline and day of 
recurrent parasitaemia, whereas re-infections were defined as no matching allelic band 
for one or more of the loci tested. Patients with recurrent parasitaemia and no available 
blood sample or negative PCR results were considered to have uncertain PCR corrected 
outcome.  
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3.5.6 Gel electrophoresis 
Restriction fragments were analysed by an agarose gel electrophoresis containing 
0.1μg/ml ethidium bromide to visualize DNA fragments by UV transillumination 
(GelDoc System, Bio-Rad, Hercules, CA, USA). 
 
 
3.6 DRUG CONCETRATION ANALYSIS 
Liquid chromatography mass spectrometry mass spectrometry (LC-MS MS) is an 
analytical method that can measure concentrations with high accuracy. Seven days after 
treatment initiation, capillary blood was collected on filter paper pre-treated with 0.75 
M tartaric acid, and stored at -20°C. Lumefantrine whole-blood concentrations were 
measured by solid-phase extraction and liquid chromatography at Bioanalytics and 
Pharmacokinetics laboratory of Dalarna University, Sweden (162).  
 
This analysis was performed for all patients, both after initial and re-treatment for Paper 
I. All infections included in Paper II had lumefantrine concentrations day 7 measured.  
 
 
3.6.1 Estimation of lumefantrine concentrations 
Lumefantrine elimination is considered to be in its log-linear phase after day 7. 
Therefore individual drug concentrations can be extrapolated to the point of interest 
according to the individual pharmacokinetic characteristics. Population 
pharmacokinetic estimates were derived from a detailed population pharmacokinetic 
study previously performed in the same setting (75). The expected drug concentrations 
on the day of hepatocyte burst were calculated for all patients with re-infections. The 
estimated day of hepatocyte burst was assumed to occur 7 days before microscopy-
based detection of recurrent parasitaemia during follow up after artemether-
lumefantrine treatment (Fig. 17). This method permitted an in vivo estimate of the re-
infecting parasite’s ability to multiply under drug pressure. 
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Figure 17. Schematic picture of parameters involved in estimating the lumefantrine concentrations at 
day of hepatocyte burst.  
 
 
3.7 BIOINFORMATICS 
Sequencher™ software version 4.6 (Gene Codes Corporation, Ann Arbor, MI, USA) 
was used to analyse all DNA sequences, assuming the 3D7 clone as the pfmdr1 
reference sequence (PFE1150w, Gene ID 813045 at NCBI RefSeq, National Center for 
Biotechnology Information Reference Sequence). 
 
 
3.8 TRANSMISSION 
Rainfall data was downloaded from the “Earth System Research Laboratory – Physical 
Science Division’s” web page www.esrl.noaa.gov/psd/, using the coordinates for 
Fukayosi, Tanzania (latitude: 6º 24´ S and longitude: 38º 40´ E). The data was provided 
in mean mm rain/day for each month.  
 
3.9 STATISTICS 
The different statistic methods used are described in brief in the result section and more 
in detail in the papers and manuscripts. Statistical significance was defined as p< 0.05. 
The statistical softwares used were STATA v.12, SigmaPlot
®
 and SPSS v.19. 
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3.9.1 Mixed infections 
It is common that patients living in moderate/high transmission settings are infected 
with more than one parasite strain, i.e. another P. falciparum strain. There is currently 
no gold standard on how to analyse these mixed infections (both alleles present at a 
particular locus). In the result section of each paper, there is an explanation on how the 
mixed infections were treated. The mixes limits analysis of haplotypes as the bigger the 
haplotype of interest, the greater the risk of mixes. If two or more loci are mixed no 
precise haplotype can be determined.  
 
 
3.10 ETHICS 
All studies included in the thesis were approved by ethics committees at the National 
Institute for Medical Research in Tanzania and at the Regional Ethics Committee, 
Stockholm, Sweden. Before patients were enrolled in a trial, the study and its objectives 
were thoroughly explained to the patients and parents/guardians, in the local language 
(Swahili), thereafter written informed consent was obtained from the parents/guardians 
of the children.  
 
The MIM/TDR study was registered at isrctn.org with identifier ISRCTN69189899. 
The CCC and Fukayosi II studies were registered at clinical.trials.gov with identifier 
NCT00454961 and NCT00336375, respectively. 
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4 RESULTS 
 
4.1 PAPER I 
Billy E Ngasala, Maja Malmberg, Anja M Carlsson, Pedro E Ferreira, Max G Petzold, Daniel Blessborn, 
Yngve Bergqvist, José P Gil, Zul Premji, Anders Björkman, Andreas Mårtensson 
 
“Artemether-lumefantrine is a well-tolerated and highly efficacious treatment for 
uncomplicated P. falciparum malaria in children in Tanzania”   
 
The aim of the study was to assess efficacy and effectiveness of artemether-
lumefantrine, and how this relates to whole blood day 7 lumefantrine concentrations. 
As well as to assess if treatment with artemether-lumefantrine selects for genetically 
distinct parasite populations among recurrent infections, with focus on the major drug 
resistance associated genes pfmdr1 and pfcrt. 
 
An open label randomized trial was performed comparing supervised artemether-
lumefantrine intake supervised (n=180) with unsupervised intake (n=179) in under five 
year old children with uncomplicated P. falciparum malaria, in rural Tanzania. 
Recurrent infections between day 14-56 were retreated within the same study arm. 
Main endpoints were PCR corrected cure by day 56 and 42 after initial and repeated 
treatment, respectively, as estimated by survival analysis. Mixed infections (i.e. both 
alleles present at a particular locus) were analysed together with the pfmdr1 N86 and 
pfcrt K76, respectively. Efficacy and effectiveness end points were analysed by 
survival analysis. Continuous data were analysed with Student’s t test, and comparison 
of categorical variables between groups was performed using the χ2 test or Fisher’s 
exact test, as appropriate. 
 
PCR corrected cure after initial treatment was 98.1% (95% confidence interval (CI) 
[94.2% - 99.4%]) after supervised intake and 95.1% (95% CI [90.7% - 98.1%]) after 
unsupervised; p=0.29. Overall, 77 supervised and 84 unsupervised patients were 
retreated with PCR corrected cure of 92.9% (95% CI [81.8% - 97.3%]) and 97.6% 
(95% CI [89.3% - 98.8%]), respectively, p=0.58. 
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Early parasitological responses to treatment could only be assessed in the supervised 
group. After initial treatment, 28.7% (51 of 178), 93.3% (166 of 178) and 98.9% (176 
of 178) of the patients had cleared parasitaemia on days 1, 2 and 3, respectively. During 
re-treatment, 49.4% (38 of 77), 98.7% (75 of 76) and 100% (75 of 75) of the patient 
achieved parasite clearance on days 1, 2 and 3, respectively.  
 
Re-infections occurred in 46.9% (82 of 175) versus 50.9 % (86 of 169) (relative risk 
[RR] 0.92 [95% CI 0.74-1.14], p=0.46) after initial therapy; and 32.4% (24 of 74) 
versus 39.0% (32 of 82) (RR 0.83 [95% CI 0.54-1.27], p=0.39) after re-treatment.  
 
Parasite genotyping showed that nearly all recurrent infections were due to re-
infections. However, in total 16 recrudescent infections (treatment failures before day 7 
and PCR confirmed recrudescent infections) occurred, of which 37.5% (6 of 16) after 
day 28. PCR corrected ACPRs were high and similar in both treatment groups after 
both initial and repeated treatment. 
 
The proportion of PCR confirmed re-infections were similar between the supervised 
and unsupervised groups after initial treatment (46.9% [82 of 175] versus 50.9 % [86 of 
169], relative risk 0.92 [95% CI 0.74-1.14], p=0.46) and after repeated treatment 
(32.4% [24 of 74] versus 39.0% [32 of 82], relative risk 0.83 [95% CI 0.54-1.27], 
p=0.39).  
 
The frequency of parasites carrying the pfmdr1 N86 allele (in pure form or mixed with 
86Y) increased from 66.9% at baseline to 80.0% and 90.3% in recurrent infections after 
initial and repeated treatment, respectively (p<0.002). No significant change in 
prevalence of pfcrt K76 allele was observed. It is to note that the baseline prevalence of 
pfcrt K76 in pure form or mixed with 76T was high, (81.5%). No child carried 
infections with pfmdr1 gene duplications at baseline or in recurrent infections after 
initial treatment. One recurrent infection carrying two copies of pfmdr1 was registered 
after the re-treatment of a previous breakthrough infection. 
 
The median lumefantrine blood concentrations on day 7 among the patients in this 
study were significantly higher in the supervised compared to the unsupervised group: 
after initial treatment (575 nM versus 367 nM; p<0.001) and after re-treatment (478 nM 
versus 310 nM; p<0.001). A significantly higher proportion of patients with 
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lumefantrine concentrations of <280 ng/ml (i.e. 529 nM), a cut-off value previously 
associated with risk of recrudescence (163), were observed in the unsupervised than in 
the supervised group (p<0.02 for all comparison). However, the lumefantrine 
concentrations did not correlate with different treatment outcomes (recrudescent 
infection, re-infection or no parasite reappearance). 
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4.2 PAPER II 
Maja Malmberg*, Pedro E. Ferreira*, Joel Tarning, Johan Ursing, Billy Ngasala, Anders Björkman, 
Andreas Mårtensson, José P. Gil. (*shared first authorship) 
 
“Using day 7 drug concentrations to estimate the drug levels that parasites 
withstand in vivo is a powerful tool to assess molecular markers relative 
importance” 
 
The aim of this study was to examine if selection of pfmdr1 SNPs among re-infections 
after artemether-lumefantrine treatment is associated with lumefantrine drug 
concentrations, and to assess the relative importance of different SNPs for the parasites 
capacity to withstand lumefantrine in vivo. 
 
We analysed two clinical trials that assessed the efficacy and effectiveness of 
artemether-lumefantrine. As a proof of concept we used measured day 7 lumefantrine 
concentrations to estimate the concentrations at which re-infections multiplied. Pfmdr1 
genotypes of these parasites were then correlated to drug susceptibility. Only pure re-
infections were included in the analysis. Mann-Whitney Rank Sum Test was used to 
compare estimated lumefantrine blood concentrations for different genotypes.  
 
Re-infecting parasites carrying pfmdr1 N86, 184F or D1246 pure alleles were able to 
survive at significantly higher median estimated lumefantrine blood concentrations 
compared with parasites harbouring their alternative alleles. The largest difference was 
observed for the N86Y SNP with 25.4 nM versus 2.08 nM (12.2 fold) between the N 
and the Y carrying parasites. For pfmdr1 Y184F and D1246Y the corresponding 
differences were 4.09 versus 34.5 nM (8.4 fold) and 15.9 versus 3.23 nM (4.9 fold), 
respectively.  
 
P. falciparum with the N86/184F/D1246 haplotype was statistically significantly less 
sensitive than the alternative haplotypes 86Y/Y184/1246Y, 31.4 versus 2.16 nM (14.5 
fold, p<0.001), and 86Y/Y184/D1246, 31.4 versus 0.678 nM (46.3 fold, p<0.001), 
respectively (Fig. 18).  
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The highest estimated lumefantrine concentration that re-infecting parasites carrying 
N86 versus 86Y could withstand differed by a factor of 35 (1184.3 nM versus 34.3 
nM).  
 
 
Figure 18. Estimated lumefantrine concentrations for re-infections carrying different pfmdr1 haplotypes 
at codon 86, 184 and 1246. Each open circle represents a re-infection. The black lines denote the median 
values, the grey the inter-quartile range.  
 
There was a distinct sub-set of parasites (n=8) able to grow at estimated lumefantrine 
concentrations above 550 nM, whereas no other parasites grew at concentrations higher 
than 300 nM. The subset represented 4.57% (8/175: CI 1.99-8.81) of the re-infections 
occurring up to 35 days after treatment initiation. These least susceptible parasites all 
carried the pfmdr1 N86 allele and had lumefantrine day 7 levels 1.8-10.3 fold higher 
than 328 nM, confirming adequate treatment and bioavailability.  
 
In Paper II the mixed infection (i.e. both alleles present at one locus) were excluded. It 
is to note that, when  mixed infection were included as a separate group the median 
estimated lumefantrine concentrations for the mixed group was lower than the median 
of the resistant group and higher than the median of the sensitive group, for all the 
pfmdr1 SNPs.   
 
A separate analysis, also not included in the Paper II, was performed on pfcrt K76T. 
Re-infecting parasites with pfcrt K76 survived at higher median estimated lumefantrine 
concentration  as compared to those with the 76T allele, 14.3 nM versus  4.1 nM (3.4 
fold difference), this did not reach statistical significance (p=0.083).  
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4.3 PAPER III 
Maja Malmberg, Billy Ngasala, Pedro E. Ferreira, Erik Larsson, Irina Jovel, Angelica Hjalmarsson, Max 
Petzold, Zul Premji, José P. Gil, Anders Björkman, Andreas Mårtensson. 
 
“Molecular surveillance of pfmdr1 and pfcrt SNPs unveiled temporal trends of 
markers associated with artemether-lumefantrine tolerance/resistance” 
 
The aim of this study was to analyse temporal trends of the prevalence of pfmdr1 and 
pfcrt SNP alleles after the implementation of artemether-lumefantrine as first-line 
treatment for uncomplicated malaria in Tanzania 2006. 
 
SNPs in the pfmdr1 N86Y, Y184F, D1246Y and pfcrt K76T were analysed from dried 
blood-spots collected during six consecutive studies from children with uncomplicated 
P. falciparum malaria in Fukayosi village, Bagamoyo District, Tanzania, between 
2004-2011. For prevalence analysis of individual SNPs, mixed infections (i.e. both 
alleles present at one locus) were analysed together with the pfmdr1 86Y, Y184, 1246Y 
and pfcrt 76T. For haplotype analysis, minority haplotypes (≤ 5%) and infections that 
were mixed at two or more loci were excluded. Infections that were mixed at only one 
locus were analysed as having both haplotypes. Logistic regression with year included 
as a continuous covariate was used to estimate the yearly changes in prevalence from 
2006 to 2011.  
 
There was a statistically significant yearly increase of pfmdr1 N86, 184F, D1246 and 
pfcrt K76 between 2006-2011 from 14% to 61% (yearly OR=1.38 [95% CI 1.25-1.52] 
p<0.0001), 14% to 35% (OR=1.17 [95% CI 1.07-1.30] p=0.001), 54% to 85% 
(OR=1.21 [95% CI 1.03-1.42] p=0.016) and 49% to 85% (OR=1.33 [95% CI 1.17-
1.51] p<0.0001), respectively.  
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During the same period the pfmdr1 NFD haplotype increased from 10% to 37% 
(OR=1.25 [95% CI 1.12-1.39] p<0.0001), whereas the YYY haplotype decreased from 
31% to 6% (OR=0.73 [95% CI 0.56-0.98] p=0.018) (Fig. 19). 
 
Figure 19. Prevalence of pfmdr1 haplotypes (N86Y, Y184F, D1246Y) in the parasite population in the 
village of Fukayosi, Bagamoyo District, Tanzania from 2004 to 2011. The arrow indicates when 
artemether-lumefantrine was introduced as first line treatment of uncomplicated malaria.   
 
When pfmdr1 haplotypes were combined with pfcrt K76T there was a statistically 
significant increase of the NFD+K haplotype from 12% to 36% (OR 1.27 [95% CI 
1.12-1.45] p<0.0001) between 2006-2011. During the same period there was a 
significant decrease of the YYD+K and YYD+T from 29% to 20% (OR 0.86 [95% CI 
0.74-1.00] p=0.041) and 17% to 0% (OR 0.59 [95% CI 0.41-0.83] p=0.003), 
respectively. There was also a decrease in prevalence of YYY+T from 19% to 2% (OR 
0.63 [95% CI 0.39-1.00] p=0.05), confirmed statistically significant by non-parametric 
trend test (p=0.003). 
 
All 390 successfully analysed samples had one copy of the pfmdr1 gene. 
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4.4 PAPER IV 
Maja Malmberg, Pedro E. Ferreira, Aminatou Kone, Berit Aydin-Schmidt, Billy Ngasala, Anders 
Björkman, Andreas Mårtensson, José P. Gil. 
 
“PfMDR1 SNPs are not selected during initial parasite clearance but play a role in 
the post-treatment prophylactic effect of artemether-lumefantrine” 
 
The aim of this study was to assess if artemether/dihydroartemisinin in vivo select for 
the same pfmdr1 and pfcrt polymorphisms as lumefantrine. As well as examine the 
characteristics of the lumefantrine window of selection after artemether-lumefantrine 
treatment. 
 
A total of 359 children were enrolled and followed-up weekly to 56 days after initiation 
of artemether-lumefantrine treatment (Paper I). A sub-population of 178 children also 
underwent daily blood sapling during the early treatment phase, i.e. day 0 to day 3. 
Genotyping of pfmdr1 and pfcrt main SNPs was compared between day 0 and day 3 
(initial parasite clearance), and day 0 and day of recurrent parasitaemia during follow-
up. For the day 0 versus recurrent infection SNP prevalence, mixed infections (i.e. both 
alleles present at one locus) were combined with the pfmdr1 86Y, Y184, 1246Y and 
pfcrt 76T. For haplotype analysis mixed infections and minority haplotypes (<3%) 
were excluded from further analysis. To compare prevalence of SNPs at baseline and at 
recurrent infection, χ2 test or Fisher’s exact test was used, as appropriate. Time to 
recurrent infection was analysed using survival analysis and comparisons between the 
different times were done using Log-Rank test and an all pairwise method. 
 
Out of 178 patients sampled at day 3, only two (1.1%) were positive by microscopy 
whereas 117 (65.7%) were positive using PCR. The analysis of these infections did not 
reveal evidence of pfmdr1 and/or pfcrt SNP selection between day 0 and day 3, during 
the artemether-lumefantrine treatment course. Genotype changes between day 0 and 
day 3 were seen in 29% (23/80), 24% (17/71), 22% (14/63) and 20% (18/91) of 
patients, for pfmdr1 N86Y, Y184F, D1246Y and pfcrt K76T, respectively. 
Nevertheless, this fluctuation did not follow any specific trends.  
 
A total of 186 patients (52%) experienced microscopically confirmed recurrent 
infection within 56 days after initiation of artemether-lumefantrine treatment. Only 7 of 
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these were defined as recrudescences according to PCR analysis, precluding any 
meaningful analysis between re-infections and recrudescences. 
 
When comparing prevalences of SNPs day 0 and among recurrent infections a 
statistically significant selection was seen for pfmdr1 N86, 184F and the pfmdr1 NFD 
haplotype. The prevalence of the pfmdr1 haplotype N86, 184F and D1246, increased 
from 28.1% (77/274) at day 0 to 100% (2/2) D7-D14 (p=0.15), 64.7% (11/17) D15-
D21 (p=0.004) and 50.0% (17/34) D22-D28 (p=0.016) among recurrent infections (Fig. 
20).  
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Figure 20. Window of selection for pfmdr1 haplotypes (codon 86, 184, 1246) after artemether-
lumefantrine treatment. The stars indicated significant difference in prevalence of NFD as compared to 
day 0.  
 
There was a 3 week difference in median day to recurrent infection between the NFD 
and the YYD haplotypes, 28 days versus 49 days respectively (p=0.0034). There was 
also a significant difference in median time to recurrent infection between NFD and 
YYY (28 days versus 38 days; p=0.0037) as well as between NYD and YYD (35 days 
versus 49 days; p=0.0039). 
 
Days since initiation of artemether-lumefantrine treatment 
* * 
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4.5 OTHER RESULTS 
 
 
4.5.1 Seasonal fluctuations 
 
It is to note that the results presented here are not included in any paper. As selection of 
pfmdr1 SNPs were seen within four weeks after treatment, we carried out an analysis to 
identify during which time of the year this was most likely to happen, i.e. how the risk 
of getting a recurrent infection during the first four weeks post-treatment varied by 
month.  
 
 
Figure 21. Seasonal fluctuations in risk of recurrent infection after treatment with artemether-
lumefantrine and rainfall in mean mm/day.  
 
Seasonal variation in the risk of recurrent infection was observed during the MIM/TDR 
study used in Paper IV. For example, patients enrolled during the month of June 
experienced the highest risk of getting a recurrent infection, 64 out of 89 (72%) 
experienced a recurrent infection within 56 days after treatment initiation, compared 
with an average of 47% during the other months (Fig. 21). The risk of recurrent 
infection within four weeks was highest during May and June (26% and 22%, 
respectively), but did not fluctuate as much as for the 56 day follow up. This peak in 
risk of recurrent infection followed ~1-2 months after the peak in rainfall.  
   49 
 
To find out if the difference in risk of recurrent infection was reflected among the 
baseline prevalence of our SNPs of interest (pfmdr1 N86, 184F, D1246 and pfcrt K76), 
a logistic regression with month as a covariate was performed.   
 
A significant increased prevalence of the pfcrt K76 was observed among pre-treatment 
infections (day 0) from May to August (Monthly OR 1.46 [95% CI 1.04-2.06] 
p=0.028). There was also a trend for increased prevalence of the pfmdr1 N86 among 
pre-treatment infections during the full period May to October; i.e. 37% (13/35) in May 
to 67% (10/15) in October (Fig. 22). No major changes in pfmdr1 184F and D1246 was 
observed.  
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Figure 22. Prevalences of PfMDR1 N86, 184F, D1246 and PfCRT K76 SNPs among pre-treatment 
infections in Fukayosi village, Bagamoyo District, Tanzania, May to October 2007. Mixed infections 
(i.e. both alleles present at one locus) were combined with the PfMDR1 86Y, Y184, 1246Y and PfCRT 
76T, respectively.  
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5 DISCUSSION 
 
5.1 ARTEMETHER-LUMEFANTRINE 
 
5.1.1 Efficacy and effectiveness of artemether-lumefantrine 
In Paper I it was concluded that artemether-lumefantrine is a highly effective and well-
tolerated treatment for children with uncomplicated malaria. This has previously been 
seen in several other studies (50). Both supervised and unsupervised intake resulted in 
high cure rates. This is supported by other effectiveness studies from East Africa (153, 
164-166) and other parts of Africa (167, 168) where artemether-lumefantrine has been 
proven to be highly effective even when the treatment was administered at home.  
 
It was shown in Paper I that re-treatment with artemether-lumefantrine within 56 days 
after initial treatment was highly efficacious. This has previously been seen in Uganda, 
Ghana, Mali and Senegal (169-174). Importantly, artemether-lumefantrine was also 
safe and well tolerated after repeated treatment, which is also supported by several 
other studies (169, 170, 172, 175). 
 
 
5.2 LUMEFANTRINE 
 
5.2.1 The use of drug concentrations day 7 to assess tolerance 
Paper II introduced a new method to assess the development of tolerance/resistance in 
vivo. By using day 7 lumefantrine concentrations and the pharmacokinetic information 
of the terminal elimination rate for our study population, the drug levels present when 
the recurrent parasites initiate its intra-erytherocytic life cycle could be estimated. This 
defines a new in vivo phenotype theoretically more similar to the ex vivo assays (i.e. 
sensitivity assessment at controlled drug exposure) than the currently used standard 
PCR-adjusted in vivo testing phenotype. By genotyping these reappearing parasites, we 
correlated the exposed drug concentrations with the presence of different SNPs alleles, 
defining the importance of these polymorphisms on the parasites ability to withstand 
lumefantrine. The proposed method has the potential of evaluating old and defining 
new potential molecular markers of in vivo tolerance/resistance. 
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The described method has limitations. One is the fact that our model of lumefantrine 
clearance was based on a population average terminal elimination half-life, derived 
from a previous population pharmacokinetic study. Although still valuable and 
sufficient for the proof of concept objectives in Paper II, it is evident that measured 
individual lumefantrine concentrations from two time points during the drug 
elimination phase would provide a more precise determination of the concentrations the 
parasite is exposed to. For future work using this method I propose to measure 
concentrations e.g. at day 7 and day 14, to get individual terminal elimination half-
lives.  
 
Another issue that must be taken into account is the fact that lumefantrine is highly 
protein bound (52). Due to this it is not known with absolute precision the actual intra-
erytherocytic lumefantrine concentrations. This makes it difficult to compare results 
from our method with in vitro methods, in terms of actual concentrations. However 
when comparing within a study, like what was done in Paper II, it is not expected that 
the high protein binding would influence the correlation between drug concentrations 
and SNPs. I assume that protein binding does not differ too much between individuals 
and that comparisons ex vivo would be more accurate in terms of actual concentration 
but this need to be further explored.  
 
The use of drug concentrations to assess tolerance/resistance is not specific for 
lumefantrine as it is a concept applicable to any long half-life antimalarial drug, where 
concentration determination methods are available. The method might be useful to 
study drug resistance in P. vivax, where the possibility to perform in vitro work is yet 
very limited. Finally, other infectious diseases, where recurrent infections and the use 
of long half-life drugs are common, could also apply this approach, e.g. leishmaniasis. 
 
 
5.2.2  The role of pfmdr1 in lumefantrine resistance 
Throughout this thesis significant contribution of specific pfmdr1 polymorphisms have 
been shown to reduce lumefantrine susceptibility and shorten post-treatment 
prophylactic effect after artemether-lumefantrine treatment (Paper I, II, and IV). 
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From our work in Paper II it was concluded that among the SNPs studied, the pfmdr1 
N86 was most important for reduced lumefantrine susceptibility. These results are 
consistent with early in vitro work using parasite clones resulting from a genetic cross 
(124), as well as from a more recent study on laboratory adapted field isolates from 
Kenya showing an association between pfmdr1 N86 and reduced IC50 values for 
lumefantrine (127). In Paper II pfmdr1 184F and D1246 were associated with reduced 
lumefantrine susceptibility. Paper IV showed that the pfmdr1 N86 and 184F are 
selected among recurrent infections upon artemether-lumefantrine treatment. These 
results are in accordance with previous studies (77, 120, 125, 126, 176). In Paper IV 
selection of pfmdr1 N86 was shown already 14 days after treatment initiation (n=3), 
which could be interpreted as selection starting almost immediately after ended 
treatment course. This points towards the importance of the pfmdr1 gene in the parasite 
response to this drug, supposedly at even relatively high lumefantrine concentrations. 
This observation is consistent with the finding in Paper II, where the pfmdr1 N86 was 
shown to be associated with a marked difference in the capacity of the parasite to grow 
in vivo under drug pressure. 
 
Reinforcing the epidemiological importance of this SNP, the World Wide Antimalarial 
Resistance Network (WWARN) is currently performing a meta-analysis of artemether-
lumefantrine clinical trials, and the preliminary results point towards pfmdr1 N86 as a 
possible risk factor for artemether-lumefantrine recrudescence (177).  
 
The pfmdr1 gene codes for the PfMDR1 transmembrane transporter, an ABC protein 
mainly located in the digestive vacuole membrane. It transports molecules from the 
cytoplasm into the lumen of the digestive vacuole (105). In silico models of PfMDR1 
have shown that amino acid 86 is located adjacent to the drug binding pocket 
suggesting a role in the kinetics of the transporter (106).  
 
The amino acid 184 is located on the outer surface of the transporter and is expected to 
also be involved in transport kinetics rather than direct interactions with drugs (106). 
This less direct interaction with the transport mechanism might explain why in our 
(Paper II) and several other studies, the Y184F has proven to be less consistently 
associated with drug susceptibility than other SNPs in pfmdr1 (116, 120, 123, 129, 178-
181).  
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The amino acid 1246 is located in the nuclear binding domain, and as such it is 
important for the ATPase activity of the protein. Mutations in the 1246 have been 
suggested to interfere with ATPase activity by influencing the communication between 
the nuclear binding domain and the trans-membrane domain (106). This is expected to 
affect the protein’s transport capabilities in a general manner, not drug specific. 
Accordingly, this SNP has been related in vitro with more or less intensity in the 
response to a broad range of quinoline drugs (117, 118). In our works (Paper IV), the 
D1246Y SNP clearly modulates the lumefantrine IC50, when comparing parasite clones 
with engineered exchanges in only the D1246Y position.  
 
Increased copy number of pfmdr1 is relatively common in South East Asia, whereas on 
the African continent pfmdr1 duplication has very rarely been found (182-184), e.g. 
none in Guinea Bissau despite ~600 samples analysed (137). In Sudan, despite low 
numbers (3/100), amplified pfmdr1 at baseline was associated with recurrent infections 
upon artemether-lumefantrine treatment (185). Interestingly, this reminds of the 
previous report by Price et al., 2006 where pfmdr1 copy number was related with less 
effective four dose artemether-lumefantrine treatment in the Thai-Burma boarder (134). 
Curiously, in South East Asia parasites analysed with amplified pfmdr1 are N86 
carriers (116, 128, 134), whereas in the African context, the few cases found have been 
86Y carriers. Accordingly, in Paper I one patient infected with a parasite carrying two 
copies of 86Y pfmdr1, was reported. This finding was confirmed by Gadalla et al., 
2011, where all three pfmdr1 amplifications detected were 86Y (185).   
 
Increased copy number of pfmdr1 is associated with an increased fitness cost (186). 
Pfmdr1 amplifications have been more frequently found among travellers returning 
from Africa (187), which might be because these non-immune subjects provide a niche 
for parasites with a reduced fitness. This raises a concern; as malaria incidence, in part 
due to improved malaria control, is decreasing in several African regions (32, 188-190), 
there is a risk that this might increase the possibility of parasites carrying pfmdr1 
duplications to become more established in the parasite population.  
 
This thesis provide additional evidence that pfmdr1 is associated with decreased 
parasite response to lumefantrine. The mechanism behind this phenotype remains to be 
understood. The topology of the pfmdr1 suggests this protein to be oriented towards the 
lumen of the digestive vacuole, with both the N- and C-terminals located in the 
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cytoplasm (110). Its transport activity is hence expected to concentrate substrates in the 
digestive vacuole (105). Assuming that the main target(s) for lumefantrine is/are 
located in the cytoplasm, hence by pumping the drug into the digestive vacuole the 
concentration of lumefantrine decreases in the cytoplasm. The digestive vacuole is 
discarded during the formation of the upcoming merozoites by the end of the intra-
erytherocytic cycle, therefore using it as a waste bin could represent a temporary but 
effective solution for evading the drug action (Fig. 23).  
 
 
Figure 23. Possible model of PfMDR1, PfCRT and PfMRP1 mediated lumefantrine resistance. The 
main target of lumefantrine (LUM) is located in the parasites cytoplasm (purple star); therefore the 
parasite can become resistant by transporting the drug into the digestive vacuole. This can be done 
more efficiently via the PfMDR1 N86/D1246 (big arrow), than the PfMDR1 86Y/1246Y (small 
arrow). Increased copies of PfMDR1 will also increase the transport capacity into the digestive 
vacuole. The PfCRT K76 cannot transport lumefantrine out from the digestive vacuole (same is true 
for chloroquine (CQ)), this results in lumefantrine accumulation in the digestive vacuole of parasites 
with PfCRT K76. The PfMRP1 can transport lumefantrine out of the cytoplasm and thereby remove it 
from its target and render the parasite resistant. 
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5.2.3 The role of pfcrt in lumefantrine resistance 
In Paper I and IV no significant selection of pfcrt K76 among recurrent infections was 
seen. In Paper I, the pfcrt K76 baseline prevalence was high (82%), and therefore 
although a trend was seen no significant selection was observed. Nevertheless, it has 
been shown to be selected among re-infections after artemether-lumefantrine treatment 
(146), and confirmed to play a role in the response to lumefantrine in vitro both through 
the analysis of culture adapted parasites (127), as well as through the study of 
genetically engineered clones that only differ at the K76T position (146). This is to a 
certain extent consistent with the influence of the pfcrt K76T polymorphism on 
mefloquine IC50s in allelic exchanged clones (142, 191). In Paper II it was observed 
that pfcrt K76 were able to re-infect at 3.4 fold higher estimated lumefantrine 
concentrations than the 76T, however this did not reach statistical significance  
(p=0.083). These somehow inconclusive results could be due to the relatively high 
baseline prevalence of pfcrt K76 or the greater importance of other genes (e.g. pfmdr1) 
for lumefantrine susceptibility. In any case, the precise importance of pfcrt K76T 
polymorphisms in lumefantrine resistance deserves a more detailed examination. 
 
 
5.2.4 The window of lumefantrine-driven pfmdr1 SNP selection and the 
short post-treatment prophylactic effect of artemether-
lumefantrine 
The window of selection is mainly determined by the terminal half-life of the drug, 
which in the case of lumefantrine is circa 3-5 days (71, 74, 75). Assuming that the log-
linear phase starts at day 5, it is expected that no major concentrations of lumefantrine 
remain in the patient after approximately 20-30 days. Supposing that it takes one week 
for parasites from hepatocyte burst until they reach levels detectable by microscopy one 
could assume that selection seen within approximately five weeks after treatment 
initiation is in part driven by lumefantrine. By using modelling the lumefantrine 
window of selection has been estimated to end at approximately 38 days (192). The 
window of selection for lumefantrine observed in Paper IV (i.e. 28 days), was in 
accordance with previous reports from Zanzibar (77, 120). In Paper IV an earlier 
opening of the window of selection (i.e. day 14) was observed, indicating that some 
parasites can actually start growing almost immediately after completed treatment 
course.  
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Lumefantrine has a limited post-treatment prophylactic effect, which is partly explained 
by the relatively short terminal elimination half-life compared to other ACT partner 
drugs, i.e. 3-5 days (71, 74, 75) as compared with 10-14 days for DEAQ (desbutyl-
amodiaquine) - the active metabolite of amodiaquine (193, 194), and ~23 days for 
piperaquine (195) (196). The disadvantage with a short post-treatment prophylactic 
effect is that it provides a shorter recovery period for patients and thereby limits the 
time for haematological recovery. From a resistance development point of view it could 
be an advantage with a short post-treatment prophylactic effect as it shortens the period 
of sub-therapeutic drug concentrations that can select for resistant infections (197).  
 
 
In Paper IV, it was shown that the prophylactic effect varied depending on the pfmdr1 
haplotype carried by the recurrent parasite. Hence, the presence of specific pfmdr1 SNP 
alleles in the parasite populations might directly reflect the artemether-lumefantrine 
post treatment prophylactic period. That is, as the prevalence of for example pfmdr1 
NFD in the parasite population is increasing, the post-treatment prophylactic effect 
could decrease. It has been shown that chloroquine and amodiaquine both select for 
pfcrt 76T and pfmdr1 86Y (198). Due to this there is reason to believe that parasites 
that are less susceptible to lumefantrine have increased susceptibility to chloroquine 
and amodiaquine. As an additional evidence to show that these molecular markers can 
have a role in the post-treatment prophylactic effect a comparison can be made between 
the different ACTs ability to protect against recurrent infections in relation to the 
baseline prevalence of pfcrt K76. Table 1 shows the percentage of recurrent infections 
up to 28 days after ACT treatment, in order by percentage of chloroquine sensitive 
parasites (i.e. pfcrt K76 carriers).   
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Table 1. Percentage of recurrent infections up to 28 days after ACT treatment, in order by percentage of chloroquine sensitive parasites (i.e. pfcrt K76 carriers). 
 
 
chloroquine 
sensitivity (pfcrt 
K76) 
artemether-
lumefantrine arm 
artesunate-
amodiaquine arm 
DHA-piperaquine 
arm 
Site 
4ABC Study Group 
(199) 
Low 16% (12/75) 8.7% (6/69) 0% (0/67) Ndola Zambia 
4ABC Study Group 0% 7.1% (5/70) 11.8% (9/76) 1.6% (1/63) 
Fougamou, 
Lambaréné 
Gabon 
Martensson et al 2005 
(200) 
3% 7% (14/197) 28% (57/206)  2002-2003 Zanzibar 
4ABC Study Group 19%  17.4% (26/149) 6.9% (10/145) Mbarara Uganda 
4ABC Study Group 22%  19.1% (35/183) 5.5% (10/182) Manhica Mozambique 
4ABC Study Group 50% 1.3% (1/75)  5.3% (4/76) Mashesha Rwanda 
Bukirwa et al 2006 
(201) 
55% 51% (102/202) 66% (133/201)  
Tororo, 2004-2005 
dec-jul 
Uganda 
4ABC Study Group 55% 43.7% (94/215)  24.5% (53/216) Tororo Uganda 
4ABC Study Group 55% 8.8% (7/80) 7.6% (6/79) 7.7% (5/65) Pamol Nigeria 
4ABC Study Group 55% 3.4% (3/87) 6.0% (5/83) 6.9% (5/72) Afokang Nigeria 
4ABC Study Group 60% 9.9% (7/71)  2.9% (2/70) Rukara Rwanda 
4ABC Study Group 72% 6.8% (14/206)  4.4% (9/206) Jinja Uganda 
Sagara et al 2012 (172) 63% 36.4% (231/634) 19.5% (117/601)  2005-2007 Mali 
4ABC Study Group 76% 60.6% (177/292) 31.4% (91/290) 14.6% (32/219) Nanoro Burkina Faso 
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In Paper III it was shown that the prevalence of pfmdr1 NFD haplotype and all the 
individual SNPs have increased significantly since the introduction of artemether-
lumefantrine. The pfmdr1 SNPs have been shown to increase also in other settings 
where artemether-lumefantrine has been implemented (202-204). As the pfmdr1 NFD 
haplotype is associated with a decreased post-treatment prophylactic effect there is a 
risk that this will lead to an increased malaria incidence. 
 
5.3 ARTEMETHER/DIHYDROARTEMISININ  
In Paper IV we report that ~25% of the patients had different pfmdr1 and/or pfcrt 
genotype, day 3 and day 0. Similar parasite population dynamics have been previously 
described upon the analysis of very polymorphic genes such as pfmsp1/2 and glurp 
(155), and concerning pfcrt and Plasmodium falciparum dihydrofolate reductase 
(pfdhfr) SNPs in travellers (205). Such differences could partly be because of the 
sequestration phenomenon, where only early and late ring stages are visible in the 
peripheral blood. They could also reflect a context of high baseline multiplicity of 
infection. The parasite dynamics indicate a possible within patient selection process 
among the drug exposed parasite populations. Accordingly, Paper IV investigated if 
there were trends of pfmdr1 selection between day 0 (pre-treatment) and day 3, a period 
in the treatment where the pulse “area under curves” (AUCs) of artemether/DHA are 
expected to be the pharmacodynamic driving force of the treatment. Such hypothesis 
was put forward, as pfmdr1 has been shown in vitro to modulate P. falciparum 
response to artemisinin derivatives (116, 118, 123, 124, 133).  
 
The absence of significant selection of any of the SNPs does not support the 
involvement of pfmdr1 in the parasite early response to the treatment. This is in contrast 
with a recent study from Kenya where the selection of the pfmdr1 N86/184F/D1246 
haplotype has been documented during the day 0 to day 3 period (206). Presently, no 
definitive explanation for these contradicting results exists.  This may simply be due to 
differences between the malaria settings (a high baseline prevalence of the N86+D1246 
haplotype (55%) in our location), or trial design (differences in drug intake). Another 
possibility could be that the parasites populations are genetically different in other – yet 
to be identified – loci associated with artemisinin susceptibility. 
 
Anyway, our negative results are in line with the present lack of evidence of 
significantly slow parasite clearance in the African continent (155, 207). Nevertheless, 
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one study from Africa has reported increased prevalence of day 1 positivity 
(microscopy based) after ACT treatment (208). Although this observation could be 
interpreted as a first sign of parasites with declining responsiveness to artemisinin, it 
might just reflect a decreased immunity in the population upon the reduction in malaria 
incidence experienced in this region.  
 
As no selection was seen day 0 to day 3, we conclude that in our setting and within the 
number of patients and SNPs analysed the artemisinin component does not select for 
the same molecular markers of tolerance/resistance as does lumefantrine. This 
suggested lack of resistance mechanism overlap is expected to prolong the useful life 
span of artemether-lumefantrine as an effective combination therapy in Africa.  
 
 
5.4 DO WE SEE RESISTANCE TOWARDS ARTEMETHER-
LUMEFANTRINE? 
ACT efficacy is based not only on the powerful anti-parasitic capacity of the 
artemisinin component, but also on a highly efficacious long half-life partner drug. The 
collapse of one of the drugs is likely to be enough to severely compromise the 
combination. In other words, resistance to artemether-lumefantrine – defined as 
treatment failure upon the administration of appropriate doses leading to adequate 
exposure – will probably happen upon a significant decrease in lumefantrine efficacy. 
Using the same argument, it is possible that a three day artemether-chloroquine 
treatment would fail in a chloroquine resistant area, as indirectly suggested in a study 
testing this (209). 
Treatment failure may however be due to inadequate drug bioavailability, i.e. not only 
truly drug resistant parasites. For slowly eliminated antimalarial drugs, day 7 
concentrations have been proposed to be a surrogate marker of the AUC and risk of 
clinical failure. Day 7 lumefantrine concentrations above 280ng/ml (529 nM) have 
been associated with low risk of treatment failure in a small pharmacokinetic 
pharmacodynamic study among adult Thai malaria patients (163). In a later clinical 
efficacy trial, at the Thai-Burma border it was shown that day 7 concentrations below 
175ng/ml (331 nM) predict recrudescence with 75% sensitivity and 84% specificity 
(134).  
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In Paper II parasites able to proliferate in conditions of estimated lumefantrine 
concentrations above the mentioned thresholds were identified. Although one should be 
cautious as to state that we have identified artemether-lumefantrine resistant parasites in 
our studies, it seems likely that the observed parasites with decreased lumefantrine 
susceptibility are the precursors of future artemether-lumefantrine resistance.  
Overall, this work supports the view that the development of resistance against 
artemether-lumefantrine is possible, probably through a process starting with an 
expected decreased of post-treatment prophylactic effect progressively reducing the 
combination treatment to an artemether monotherapy (210), and only three days of 
artemether is sufficient for therapeutic cure.  
 
In the study described in Paper I no clear correlation between low day 7 lumefantrine 
concentrations and recrudescence was seen. This finding was also reported in previous 
trials (167). However in the effectiveness study included in Paper II there is a 
significant association between low day 7 lumefantrine concentrations and 
recrudescence (i.e. recrudescences had median lumefantrine concentrations of 183 nM 
versus re-infection 388 nM and no recurrent infection 410 nM) (153). In a multicentre 
trial comparing a dispersible tablet formulation with a tablet formulation administered 
crushed, it was noted that there was a tendency for lower lumefantrine concentrations 
among treatment failures (211).  
 
 
5.5 CONTRIBUTING TO THE UNDERSTANDING OF A COMPLEX 
SCENARIO: IN VIVO PARASITE DRUG SUSCEPTIBILITY 
 
The current PCR adjusted in vivo testing used to evaluate antimalarial drug efficacy has 
some concerns. By only using one time point, not all parasite populations are visible in 
the peripheral blood, and important information is thereby lost (154). Also the method 
used to extract and amplify DNA will influence the sensitivity and hence the detection 
of minor parasite populations (212). This leads to different laboratories having different 
outcomes for the same markers, with the same biological material (213). 
 
There is also the risk that - in particular in a setting with low genetic diversity in the 
parasite population - a patient might be re-infected with a parasite that looks identical to 
the one that was there pre-treatment, and thereby wrongly classified as a recrudescence. 
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Conversely, in setting with diverse parasite populations, recurrent infections occurring 
up to day 14 are often classified as re-infections (214). Such “re-infections” are 
unlikely, considering that it takes approximately 7 days from the moment of the 
infective bite until the hepatocyte burst, and approximately 7 days from hepatocyte 
burst to microscopically detectable levels of parasites in the peripheral blood 
 
The WHO guidelines were designed to evaluate how well the drug cleared parasites 
and cured the patient. However it was not designed to study resistance development. 
Another limitation with the WHO guidelines currently used to evaluate antimalarial 
drug efficacy is that it does not take into consideration the post-treatment prophylactic 
effect. In Paper II we propose that by using drug levels day 7 and estimating the 
concentrations that emerging parasites can withstand, will provide a more accurate 
definition of individual infections as carrying tolerant/resistant parasites. For improved 
estimates we suggest to determine drug levels also at day 14, to get individual estimates 
of the terminal elimination rate. This method is expected to be highly specific, i.e. a 
highly tolerant/resistant parasite will be detected and a false classification is unlikely. 
Our proposed method will only be able to detect tolerant/resistant parasites that appear 
during the early post-treatment period, as such it is prone to low sensitivity, i.e. 
parasites that have the ability to withstand high drug concentrations may just happen to 
emerge late during the follow up and thus not to be considered as tolerant/resistant.  
 
Recent findings from work done in rodents suggest that superinfections (infection with 
several Plasmodium strains at the same time) are regulated trough the host’s iron 
regulatory hormone hepcidin (215). It is likely that this is also the case in humans. If 
that is so, then when several sporozoites with genetically different parasite strains are 
injected and migrate to the liver, it could be so that not all strains then immediately start 
multiplying, and burst from the hepatocyte and infect RBCs. Some strains could 
become growth arrested in the liver cells, a process probably mediated by the host’s 
hepcidin-levels. The synthesis of hepcidin has been shown to follow blood stage 
parasite in a density dependent manner. Therefore, when one infection has been 
cleared, hepcidin levels decrease and the parasite strain previously growth arrested in 
the liver can start growing again (215). This new understanding of the complex 
interactions between the parasite and the host challenges our view of a re-infection as 
this concept proposes that a newly appearing parasite strain does not necessarily need 
to come from a new infective mosquito bite. 
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5.5.1 Seasonal fluctuations 
Malaria incidence is highly dependent on mosquito prevalence. Access to water needed 
for the development of mosquitos increases dramatically during rainy seasons, leading 
to strong natural correlation between rainfall and malaria transmission, resulting in an 
increased incidence of the disease, usually with a few weeks lag time. The re-infection 
rate is therefore observed to vary throughout the year, following the seasons (172, 201). 
 
In the MIM/TDR study, a seasonal variation in the rate of recurrent infections was 
observed (Fig. 21). During the period when the risk of recurrent infection four weeks 
after treatment is high, i.e. during the high transmission season, the drug selective 
pressure will also be higher. This could give rise to an increased selection of 
tolerant/resistant parasites.  
 
To assess if these differences in risk of recurrent infection was reflected among the 
baseline prevalence of our SNPs of interest (pfmdr1 N86, 184F, D1246 and pfcrt K76), 
a logistic regression with month as a covariate was performed. During the time period 
when the risk of getting a recurrent infection within four weeks was greatest (i.e. 
patients who started treatment in May and June), no major increase of our SNPs of 
interest were observed at baseline infections. A significant monthly increase in the pfcrt 
K76 among pre-treatment infections May to August was seen, which could be due to 
the increased fitness of the K76 as compared to 76T (216). A trend for increased 
pfmdr1 N86 was also observed from May to October. It is to note that the sample size 
for this analysis was relatively small, wherefore the results should be interpreted with 
caution.  
 
In Paper IV, it was concluded that the days of post-treatment prophylactic effect is 
highly dependent on the pfmdr1 status of recurrent parasites. Therefore, the risk of 
getting a recurrent infection varies with rainfall and pfmdr1 SNPs (217). 
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6 CONCLUSIONS  
 
These are the overall conclusions from this thesis: 
 
 
Paper I 
 Artemether-lumefantrine is highly effective both in a real life like scenario and 
under ideal conditions.  
 Patients with unsupervised drug intake have lower lumefantrine blood 
concentrations day 7 than the patients with supervised intake, but the cure rates 
between the two groups are not different.  
 Recurrent infections that appear after artemether-lumefantrine have specific 
genetic characteristics. There is a significant selection of pfmdr1 N86 and a 
trend for increased prevalence of pfcrt K76. 
 One patient was infected with a parasite carrying two copies of the pfmdr1 
gene. 
 
Paper II 
 Selection of pfmdr1 SNPs among re-infections after artemether-lumefantrine 
treatment is associated with lumefantrine drug concentrations.   
 Patients’ lumefantrine concentrations in combination with pharmacokinetic 
parameters and genotyping of recurrent parasites post-treatment can be used to 
assess the relative importance of different SNPs for the parasites capacity to 
withstand lumefantrine in vivo. 
 In vivo, the pfmdr1 N86/184F/D1246 is able to withstand 15 fold higher 
lumefantrine concentrations than the pfmdr1 86Y/Y184/1246Y.  
 
Paper III 
 From 2004 to 2011, the prevalences of parasites with pfmdr1 N86/184F/D1246 
and pfcrt K76 have increased significantly after the implementation of 
artemether-lumefantrine as first line treatment for uncomplicated malaria in 
Tanzania. 
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Paper IV 
 Artemether/dihydroartemisinin does not appear to select for the same pfmdr1 
and pfcrt molecular markers as lumefantrine in vivo.  
 The lumefantrine window of selection appears to start almost immediately after 
completed artemether-lumefantrine treatment course and lasts for four weeks.  
 Within the lumefantrine window of selection pfmdr1 N86 and 184F were 
significantly selected. 
 The post-treatment prophylactic effect after artemether-lumefantrine treatment 
can vary up to three weeks depending on the pfmdr1 polymorphisms of 
parasites causing the recurrent infection.   
 
   65 
7 PERSONAL REFLECTIONS AND FUTURE 
PERSPECTIVES 
 
I would like in this section to share some of my personal reflections and future 
perspectives in relation to the main findings of this thesis.  
 
To me the most important contribution of this work is the development of a new 
method to study tolerance/resistance development in vivo, based on the use of drug 
concentrations (Paper II). This method has the potential of accelerating the discovery 
and establishment of molecular markers of resistance, and is applicable to other drugs 
than lumefantrine and to other diseases.   
 
This thesis has shown that pfmdr1 SNPs contribute to the parasites lumefantrine 
susceptibility. In order to fully understand the importance of these SNPs and the 
mechanism behind lumefantrine resistance more work is needed and it would be very 
interesting to follow up these findings with controlled transfection experiments.  
 
Trend analysis is a crude but important tool to understand resistance development and 
spread. The trend of increased pfmdr1 NFD shown in Paper III could be an early 
warning sign of decreased lumefantrine efficacy and should be followed up with close 
monitoring of artemether-lumefantrine efficacy. I believe that molecular markers play 
an important role in the evaluation and surveillance of emerging drug resistance 
especially in settings where malaria incidence is decreasing, as this makes clinical trials 
even more costly and time consuming to conduct. Molecular markers may also be 
valuable in resource poor settings, where RDTs can be collected and later on used as a 
DNA source for molecular genotyping/surveillance (218).  
 
When artemether-lumefantrine was introduced it was in the era of chloroquine 
resistance. During many years chloroquine had been selecting for a parasite population 
with mainly pfcrt 76T and pfmdr1 86Y. From what we know now about lumefantrine, 
at least in regards to these two SNPs, highly chloroquine resistant settings were the 
optimal environment for artemether-lumefantrine to be efficient.  
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In Paper III it was shown that the vast majority of the parasite population in Fukayosi, 
just like in other places in Africa, have now become pfcrt K76 (and therefore 
supposedly chloroquine sensitive). If this is the case maybe reintroducing chloroquine 
would be an option. The advantage with chloroquine is that it is a very cheap, safe and 
well-tolerated drug. The disadvantage is the risk for resistance to develop rapidly again. 
This could potentially be overcome by giving higher total dose of chloroquine, but 
divided into smaller and more frequent doses as was previously done successfully in 
Guinea Bissau (219). 
 
Artemether-lumefantrine has been shown to be highly effective, however considering 
the previously mentioned limitations with evaluation of antimalarial drug efficacy and 
with the results from this thesis, I believe we need to raise the question: how long will 
artemether-lumefantrine remain effective? I think that we in a proactive manner should 
start thinking about and implementing ways to prolong the life-span of artemether-
lumefantrine. One option could be the use of multiple first line treatments (220), e.g. 
introducing DHA-piperaquine as an additional first line treatment to be used in parallel 
with artemether-lumefantrine. An alternative to parallel use could be to use DHA-
piperaquine during the period when the risk of recurrent infection within four weeks 
after treatment is highest, and to use artemether-lumefantrine during the remaining 
year.  
 
The differences in post-treatment prophylactic effect observed in Paper IV makes me 
wonder; what is the reason behind it? Can it get even shorter? And how short post-
treatment prophylactic effect can be considered acceptable from a clinical point of 
view? 
 
One way that might help to prolong the post-treatment prophylactic effect of 
artemether-lumefantrine is by increasing the exposure to lumefantrine. It was recently 
shown among children in Uganda on antiretroviral therapy, that those receiving a 
lopinavir-ritonavir based antiretroviral therapy had a 41% reduced incidence of malaria 
as compared to those on Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-
based antiretroviral therapy. This was primarily due to a major reduction in the risk of 
recurrent malaria after treatment with artemether-lumefantrine. Children in the 
lopinavir-ritonavir arm had significantly higher lumefantrine concentrations day 7 
which was thought to be the result of inhibition of P450 3A4 metabolism by ritonavir 
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(221). This way of increasing exposure to lumefantrine is likely to be more efficient 
than increasing the dosing as it appears that absorption of lumefantrine is a saturable 
process (74). In line with this work, future studies should investigate the use of 
pharmacological enhancement to prolong the post-treatment prophylactic effect of 
artemether-lumefantrine. 
 
I’m hesitant to state that artemether-lumefantrine resistant parasites are seen in the 
studies included in this thesis. However, I do believe we need to improve the current 
tools used to assess antimalarial efficacy and I’m concerned about the observed 
evolution of less lumefantrine susceptible parasites. 
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